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ABSTRACT 
Type 1 diabetes (T1D) is a disease that results after a selective destruction of the 
insulin-producing β-cells in the pancreas. The lack of β-cells renders T1D patients 
completely unable to synthesize and secrete insulin, which leads to a life-long need of 
exogenous insulin for survival. The cause for this selective destruction is still debated, 
but both genetic and environmental factors have been shown to regulate susceptibility 
and development of T1D. Together with my colleagues, I have studied different aspects 
of the observed link between enterovirus (EV) infections, especially those by 
Coxsackievirus serotype B (CVB) and the development of T1D. 
 
CVB infections may accelerate diabetes development in diabetes-prone mice. This 
acceleration can however be abrogated by activated iNKT cells. By studying how 
stimulated or non-stimulated iNKT cells differently regulated macrophages after a 
CVB4 infection, we have suggested a mechanism for this suppression. We showed that 
iNKT cells activated in the presence of CVB4 induced suppressive functions in islet-
resident macrophages, which then inhibited diabetes development in diabetes-prone 
mice.  
 
Recently, two multi-center studies suggested CVB1 infections to be diabetogenic, 
causing human β-cell autoimmunity and T1D development. The identification of a 
specific virus strain suggests a possibility to use a vaccine, in order to reduce diabetes 
development. We therefore developed a prototype CVB1 vaccine and tested the 
functions and safety profile in two different animal models. We showed that the 
vaccine was well tolerated and protected mice from CVB1 infection. Furthermore, we 
also observed that the vaccine was safe in an autoimmune setting where we showed no 
acceleration of diabetes development or triggered autoimmunity in vaccinated mice 
prone to develop autoimmune diabetes. 
 
Despite the findings that CVB1 may be diabetogenic, an inverse correlation between 
the incidence of T1D and the number of recorded EV infections have been observed. 
This counterintuitive observation may be explained by the poliovirus hypothesis, 
stating that a low herd immunity due to a low frequency of virus infections in the 
population, may make children that lack maternally transferred antibodies more 
susceptible to diabetogenic infections. Hence, we tested if maternally transferred 
antibodies transferred could protect offspring from a diabetogenic CVB3 infection in a 
mouse model for virus-induced diabetes. Our results support a role for the poliovirus 
hypothesis in explaining the observed inverse correlation between T1D incidence and 
prevalence of EVs. 
 
The primary site of replication for CVBs is in intestinal epithelial cells (IECs), but what 
regulates the viral spread to other targeted organs is not known. IFN-λs may regulate 
permissiveness to the infection. We therefore investigated how intestinal epithelial cells 
respond to IFN-λ stimulation and found that they could upregulate specific antiviral 
proteins. This suggested that IECs could be used in a model to study if IFN-λs can 
regulate IEC permissiveness to CVBs. 
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Prologue 
 
“Type 1 diabetes is a chronic autoimmune disease characterized by the immune-
mediated destruction of the insulin-producing β-cells in the pancreas”. In various 
literary formulations, this message is classically delivered in the first sentence of most 
scientific articles about human type 1 diabetes (T1D). A following sentence usually 
suggests that “this or that” can cause, trigger or affect the autoimmune attack on the β-
cells but the truth is; we don’t know. We can’t prevent the disease and we can’t cure it, 
we can only treat patients with life-long supplementation of exogenous insulin. Despite 
years of research and billions of dollars spent, science still lacks an answer to the quite 
simple question, asked by every child developing T1D; 
- Why did I get diabetes?  
 
A simple message understood from all scientific articles written about T1D is that this 
is truly a complex disease. As indicated from both human and murine studies, genetics 
and environmental factors can both regulate susceptibility to T1D, but exactly how this 
is done is still unknown. The rise in T1D incidence observed world-wide cannot be 
explained by genetic factors alone, but rather points to an environmental change that 
exposes genetically susceptible individuals to a higher risk for developing T1D. Also, 
we may never isolate one single factor that can explain the etiology of all T1D cases, 
but rather find that the disease is heterogeneous in nature, with several different factors 
individually regulating destruction of the β-cells, all leading to the same result, namely 
T1D development.  
 
However, one independent environmental factor suggested to be involved in T1D 
development in some patients is enterovirus (EV) infections, especially those of 
Coxsackievirus serotype B (CVBs). Numerous observations have linked EV infections 
to T1D and triggering or acceleration of β-cell autoimmunity. Recently, CVB1 
infections were specifically suggested to trigger both the development of β-cell 
autoimmunity and T1D development. The identification of specific virus strains 
associated with T1D development suggests that one could potentially develop a vaccine 
targeted at specific viruses, in order to protect genetically susceptible individuals from 
developing virus-induced T1D.  
 
The aim of this thesis was to further investigate if and how CVBs are involved in the 
development of T1D and to develop strategies to prevent CVB infections through the 
use of vaccines and novel vaccination strategies. I will explain how my results can be 
interpreted and further discuss what this means in broader terms. I will also give my 
own thoughts on future perspectives for T1D research and what I think future T1D 
research projects should focus on. 
 
 
 
 
 
 
LIST OF ABBREVIATIONS 
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APC Antigen-presenting cell 
BCR B-cell receptor 
CAR Coxsackie and Adenovirus Receptor 
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CVB Coxsackievirus serotype B 
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1 INTRODUCTION 
Several different forms of diabetes exist, with the two most common forms denoted 
type 1 (T1D) and type 2 diabetes (T2D). Both forms are characterized by crucial 
deficiencies affecting production and function of insulin, a hormone involved in 
glucose metabolism. Insulin is produced by the beta (β) cells in the pancreas and is 
crucial for most cells to absorb and utilize glucose from the blood as an energy source.  
 
In laymen terms, the cellular function of insulin can be depicted as a key unlocking and 
opening a door, where insulin is ‘unlocking’ and activating specific cellular functions 
involved in glucose uptake. The difference between T1D and T2D can also be 
simplified and explained using this analogy; T1D is the result of virtually no insulin 
being produced or secreted, resembling a lost key. T2D results from insulin resistance 
in combination with insufficient amounts of insulin, which can be compared to using a 
key that does not fit or a non-functional lock, in combination with too few or no keys. 
For both diseases, the cellular inability to absorb glucose results in high concentration 
of glucose in the blood (hyperglycemia), a fatal condition if not properly treated.  
 
According to the World Health Organization (WHO) and the American Diabetes 
Association (ADA), about 90% of all diabetes cases are considered to be T2D and 
between 5-10% are considered to be T1D cases [1, 2]. However, these figures might 
not truly reflect the reality since numerous T2D cases actually require insulin treatment, 
a hallmark for T1D. 
 
Development of T2D is hereditary, but also highly related to a sedentary or unhealthy 
life style and diet, and most patients that develop the disease are obese. Treatment 
normally requires a change of life style and regular exercise, in combination with anti-
diabetic drugs to stimulate insulin sensitivity. Some patients may also require insulin 
treatments.  
 
However, the more severe type of diabetes, T1D, is as we know today not dependent on 
life style, but rather a chronic disease with a complete lack of endogenous insulin 
production. Before the discovery of insulin [3], T1D was inevitably fatal, but today 
patients survive through life long treatment with exogenous insulin. The following 
chapters will focus only on T1D, the etiology of the disease and potential preventative 
therapies. 
 
1.1 TYPE 1 DIABETES 
Human T1D, previously called insulin-dependent, juvenile or childhood-onset diabetes 
mellitus, results from a selective destruction of the insulin-producing β-cells in the 
pancreas, rendering patients completely unable to synthesize insulin. The ADA have 
described three significant hallmarks of T1D, used to distinguish T1D from other forms 
of diabetes [2]: 
1. Immune-mediated β-cell destruction 
2. Insulin deficiency 
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3. Low or undetectable levels of C-peptide, a cleavage product formed when 
active insulin is synthesized. 
 
T1D development seems to have two peaks, between 5-7 years of age and in 
adolescence in close proximity to puberty (reviewed in [4, 5]). T1D can however 
develop at any age, even in adults. Due to the previous classification of T1D as juvenile 
diabetes, it has been suggested that possibly 5-15% of all T2D cases are misdiagnosed 
cases of adult T1D, implicating that the percentage and number of T1D cases 
worldwide is considerably underestimated [5, 6]. Adult onset of T1D has previously 
been considered to be a unique form of diabetes, called Latent Autoimmune Diabetes in 
the Adults (LADA), but recent studies suggests that LADA actually falls under the 
T1D classification [7].  
 
T1D patients require life-long treatments with exogenous insulin. Due to the acidic 
environment in the stomach, insulin cannot be delivered in tablet-form, hence insulin 
administration has to be done via subcutaneous injections prior to every meal. In 
addition to this, patients may also need injections with long-lasting insulin, in order to 
obtain a baseline effect of insulin needed to control the metabolism. The recent 
development of smart insulin pumps has greatly benefitted T1D patients, with a 
reduced number of daily injections and more stable blood glucose levels. T1D is 
however still a severe disease, and many patients still have difficulties with controlling 
and regulating their blood glucose levels, despite the recent development in diabetes 
care and equipment [4]. The lack of controlled and stable blood glucose levels can lead 
to severe short- and long-term complications. Short-term, life-threatening 
complications are ketoacidosis and hypoglycemia, whereas long-term diabetes-related 
complications include microvascular disease like nephropathy, neuropathy and 
retinopathy as well as cardiovascular and cerebrovascular disease [4]. 
 
1.2 THE HISTORY OF T1D 
The first description of a disease thought to be T1D was found in a manuscript by the 
Egyptian physician Hesy-Ra from around 1500 BC, describing patients suffering from 
polyuria, one of the earliest signs of T1D development [8]. The word diabetes is 
derived from the Greek word diabainein – to pass through, and was first used by the 
Greek physician Arateus around 250 BC, when he described the disease as the 
“meltdown of flesh and limbs into urine” [8]. The addition of the Latin word mellitus – 
sweet as honey, was done in 1674 by Thomas Willis at the University of Oxford, after 
tasting ”wonderfully sweet” urine from T1D patients [8]. The name diabetes mellitus 
hence refers to one of the first symptoms of disease development, polyuria, and the 
sweet the urine secreted by the patients. For years, the sweetness of urine was used as a 
diagnostic marker for T1D. 
 
With the exception of somewhat functional diets and fasting cures, which at best 
resulted in a few additional years of survival, T1D was untreatable and inevitably fatal. 
It took until the end of the 19th century before some major medical breakthroughs 
resulted in the discovery and isolation of insulin, which facilitated the development of a 
functional treatment for T1D.  
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In 1869, the German medical student Paul Langerhans discovered the specific cell 
clusters in the pancreas that we know as “the islets of Langerhans” [9]. The French 
pathologist Gustave-Édouard Laguesse thereafter coined the name of these cell clusters 
“the islets of Langerhans” in 1891 [9]. The initial breakthrough was however made in 
1889, when Joseph von Mering and Oskar Minkowksi at the University of Strasbourg 
found that a pancreatectomy of dogs resulted in them developing T1D ([8] and the 
original German paper [10]). In 1901, the American pathologist Eugene Opie 
discovered morphological differences in the islets of Langerhans of T1D patients, 
linking the islet function to T1D.  
 
In 1920, spurred by these findings, Frederick Banting initiated collaboration with 
Professor James Macleod in Toronto. After being assigned Charles Best as a lab 
assistant, Banting and Best were the first to isolate functional insulin in 1921 and they 
managed to successfully treat pancreatectomized dogs with bovine pancreatic islets 
extracts for an extended period of time [3, 8]. In collaboration with Macleod and 
chemist James Collip, they attempted the first human trial in 1922, by injecting 
Leonard Thompson, a 14-year-old diabetic boy, with insulin purified from bovine 
pancreata [8]. With the help of the medical company Eli Lilly and Company, they 
improved the purification process of the islets extracts, and in 1923 insulin was made 
commercially available for patients in Canada and the United States [8]. Due to the 
extraordinary fact that Banting and Best made their patented discovery of insulin 
available free of charge, T1D patients everywhere could quickly benefit from the novel 
insulin treatments. Banting and Macleod were awarded the Nobel prize in Physiology 
or Medicine in 1923, a prize they immediately shared with Best and Collip [8].  
 
After being limited to harvesting insulin form animal organs, the next major 
breakthrough was made in 1982, when the joined effort by Genentech and Eli Lilly 
launched the first recombinant human insulin [8]. Today there are several different 
forms of insulin available on the market, all produced through the use of recombinant 
technology in yeast or bacteria.  
 
1.3 T1D INCIDENCE 
The incidence of T1D has increased rapidly world wide during the last decades [11-14]. 
There are marked differences in the observed incidence in the age interval 0-14.9 years, 
with incidence figures ranging from <1 per 100.000 individuals in low incidence 
countries to >60 cases per 100.000 individuals in Finland, the country with the highest 
incidence of T1D [11-15]. The T1D incidence in Sweden was recently shown to be 
almost 44 cases per 100.000 individuals, which puts Sweden as having the second 
highest T1D incidence in the world [16].  
 
The rapid increase in T1D incidence is alarming and, even though predictions should 
be taken with cautions, two prospective studies have predicted a 30-70% total increase 
in T1D incidence by the year 2020 [14, 15].  
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1.4 THE PANCREAS 
The human pancreas is a unique gland with both exocrine and endocrine functions. The 
exocrine functions include production of several digestive enzymes involved in 
breaking down carbohydrates, proteins and lipids, and secreted through the pancreatic 
duct into the duodenum. However, of focus in this thesis are the functions, or rather the 
lack of functions, of the endocrine part of the pancreas.  
 
The endocrine parts of the pancreas are spread throughout the organ as small cellular 
clusters, known as the islets of Langerhans. These clusters may only represent about 1-
2% of the total pancreatic mass, but they are crucial for survival [17]. The islets consist 
of several types of cells, all with their own unique endocrine function. The most 
abundant cell type in the islets are the insulin-producing β-cells, representing about 
70% of the functional islets cells [18]. The glucagon-producing alpha (α) cells account 
for about 10% and the somatostatin-producing delta (δ) cells, pancreatic polypeptide-
producing (PP) cells and ghrelin-producing epsilon (ε) cells represents 3%, 19% and 
1%, respectively (reviewed in [18]). Since the islets are vascularized, endothelial cells 
may also account for a part of the total islet mass. 
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2 BASIC IMMUNOLOGY 
The immune system is protecting us against all kinds of infectious agents through a 
network of specialized immune cells, lymphoid organs and signaling cytokines [19]. 
The regulation of all these cells and their functions is delicately balanced; an inactive 
immune system may result in tumor formations and severe infections, whereas an 
overactive immune system may increase the risk for developing allergies and 
autoimmune diseases [19]. The immune system is commonly divided in two arms; the 
innate immune system and the adaptive immune system. However, the two-way 
signaling between them is crucial for a mounting a proper immune response. For 
example, T-cells would not be able to function properly without the stimulation by 
dendritic cells and other antigen-presenting cells (APCs) and activated T-cells can 
further potentiate macrophages to become more aggressive in response to infectious 
agents. The following sections will provide a simplified description of the immune 
system, divided into the innate and the adaptive immune system, and some important 
concepts needed to understand the relevance for the immune system in the light of 
antiviral responses and autoimmunity. 
 
2.1 THE INNATE IMMUNE SYSTEM 
The innate immune system refers to the cells and functions that provide the host with 
an immediate defense against pathogens. The cellular components of the innate 
immune system include macrophages, neutrophils, basophils, eosinophils, monocytes, 
dendritic cells, natural killer (NK) cells and invariant Natural Killer T-cells (iNKT) 
[20]. All the aforementioned cells can be rapidly activated upon infection and act 
together with the complement system, numerous cytokines and acute phase proteins, in 
order to clear the host from pathogens. The innate immune system can orchestrate a 
grand attack on any pathogen it can recognize through pathogen associated molecular 
pattern receptors (PAMPs) or the lipid antigen-presenting CD1d. However, the 
activation of the innate immune system can also lead to tissue damage due to the 
relative unspecific highly inflammatory milieu [20]. 
 
2.1.1 iNKT cells 
Despite being closely related to the T-cells of the adaptive immune system, the iNKT 
cells are usually considered to be part of the innate immune system [21]. iNKT cells 
express a highly restricted αβ T-cell receptor (TCR) with the α-chain Vα24Jα18 in 
humans and Vα14Jα18 in mouse, specifically recognizing lipid-antigens presented by 
CD1d [22, 23]. Upon activation, iNKT cells can produce and secrete, for example, 
large amounts of IL-4 and IFN-γ to activate macrophages and also antiviral T-cells of 
the adaptive immune system [22, 24]. The synthetic ligand α-galatosylceramide (αGC) 
is commonly used to experimentally stimulate and activate iNKT cells. The iNKT cells 
have different roles as a regulatory cell in the immune system. iNKT cells can both 
promote antiviral responses but also regulate autoimmunity and dampen autoreactive 
T-cells [25, 26].  
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2.1.2 Macrophages 
Macrophages are important phagocytic immune cells of the innate immune that also act 
as APCs [27]. Monocytes from the blood stream can migrate to inflamed and infected 
sites due to chemotaxis and once there, they can differentiate into macrophages [27]. 
After phagocytic uptake of pathogens, macrophages can present processed antigens to 
orchestrate and activate the adaptive immune activation [28]. Macrophages are found in 
most tissues in the human body [27].  
 
Generally there are two main subtypes of macrophages. The M1 macrophages are 
involved in inflammatory responses by secreting for example IL-1β, IL-6, IL-12 and 
TNF-α [28]. Activated M1 macrophages are commonly referred to as classically 
activated macrophages. The other subtype is the M2 macrophages, which have been 
suggested to have an important role in tissue repair and immune suppressive functions 
[28]. M2 macrophages produce and secrete anti-inflammatory cytokines for example 
IL-10 and TGF-β [28]. 
 
2.2 INTERFERONS 
The interferons (IFNs) are an important group of cytokines with functions closely 
related to the innate immune system. IFNs are involved in the induction of the cellular 
antiviral defense and they can indirectly interfere with virus replication through the 
induced upregulation and transcription of antiviral effector genes. IFNs can also signal 
systemically to orchestrate an immune response towards an infecting virus [29].  
 
Upon infection, the cell starts to produce and release IFNs, to signal to other cells to 
enter an antiviral state and prepare for encountering viruses [29, 30]. The IFN-induced 
antiviral state is regulated by interferon-stimulated genes (ISGs), encoding numerous 
antiviral effector proteins (reviewed in [31, 32]). The aim of these proteins is to reduce 
permissiveness to infections. Secreted IFNs can act locally through autocrine and 
paracrine signaling pathways to signal to surrounding cells but also systemically in 
order to activate antiviral immune cells [29, 30]. In an antiviral state, the cell responds 
vigorously to pathogens resulting in early recognition of pathogens or potentially 
apoptosis, since the cell is also primed to undergo apoptosis if successfully infected. 
Altogether this leads to a reduced viral replication and spread. IFNs are considered to 
be crucial for controlling virus infections. 
 
There are three different types of human IFNs; 
• Type I IFNs, sometimes only referred to as IFN-α/β, consists of thirteen 
different IFN-α subtypes, a single isoform of IFN-β, and the somewhat less 
abundant IFN-κ, -ω and -ε. Most cells in the body can express and respond to 
type I IFNs in response to virus infections [29]. 
• The type II IFN group only consists of one single isoform, IFN-γ, which is 
mostly produced by activated NK-, iNKT-, TH-cells and macrophages. IFN-γ 
expression can amplify the antiviral activity of type I IFNs and is also critical 
for antitumor responses and for controlling intracellular bacteria like 
mycobacterium tuberculosis [29].  
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• Type III IFNs or IFN-λs, include four isoforms; IFN-λ1 (IL-29), IFN-λ2 (IL-
28A), IFN-λ3 (IL-28B) and the quite rare IFN-λ4 [29, 30]. The expression of 
the receptor for IFN-λs have been shown to be quite restricted and mostly 
expressed by epithelial cells, hence suggesting a specific local role for IFN-λs. 
IFN-λs are might be expressed by infected cells, mainly of epithelial origin, but 
monocyte-derived dendritic cells and plasmacytoid dendritic cells have also 
been shown to produce and secrete IFN-λs (reviewed in [30]). 
 
 
2.3 THE ADAPTIVE IMMUNE SYSTEM 
The adaptive immune response is very potent and specific, but significantly slower in 
responding to pathogens [33]. The main components of the adaptive immune system 
are T- and B-cells, also called T- and B-lymphocytes [27]. These cells’ respective 
receptors, the TCR and B-cell receptor (BCR), are highly diverse thanks to a very 
elegant rearrangement mechanism [33] and they are highly specific for their respective 
antigens. Antigens are presented to T- and B-cells through interactions of the TCR and 
BCR with peptides bound to MHC class II on APCs or MHC class I, which is 
expressed by virtually all nucleated cells [27]. Infected cells can upregulate expression 
of MHC class I, in order to facilitate recognition of viral peptides by the immune 
system [27]. 
 
2.3.1 T-cells 
There are numerous different subpopulations of T-cells, but only four main subtypes 
and their functions are described in this simplified overview [27, 33]; 
1. The T-helper cells (usually denoted TH-cells or CD4+ T-cells due to their 
distinct expression of CD4) are mainly responsible for activating other immune 
cells through co-stimulatory molecules, for example activation and maturation 
of B-cells and activation of cytotoxic CD8+ T-cells [27].  
2. The cytotoxic T-cells (TC-cells or CD8+ T-cells, due to the expression of CD8 
on the surface) are potent killers of virus-infected cells or tumor cells. These are 
crucial components in controlling a virus infection since they recognize viral 
peptides presented by MHC class I on infected cells. Upon engagement, TC-
cells can kill infected cells through the release of cytotoxins (e.g. perforin and 
granzyme B) and by direct cell-cell contacts [27]. 
3. Memory T-cells can be either CD4+ or CD8+ and once activated by their 
respective antigen, they can persist for a long time. Upon re-exposure to the 
antigen, these cells can quickly expand to activate other immune cells [27].  
4. The regulatory T-cells (Treg cells or suppressor T-cells) are key components in 
dampening for example other T-cell responses after a virus infection is cleared. 
Suppression is mainly mediated through the cytokines IL-10 and TGF-β [27]. 
Treg cells are crucial for maintain immunological tolerance [27]. 
 
2.3.2 B-cells 
B-cells are formed in the bone marrow and their main functions are to produce 
antibodies and act as APCs [33]. Upon activation thorough the BCR, antibodies are 
  8 
produced against foreign antigens such as viral and bacterial proteins, and the 
antibodies can opsonize infectious agents or render them incapable of infecting host 
cells. Through genomic rearrangement and class switching, the B-cells can produce 
antibodies with virtually endless specificities [27]. The five main classes of human 
antibodies are IgA, IgD, IgE, IgG and IgM, all with different distinct functions [27, 33]. 
The two isoforms IgA and IgG also have subclasses, IgA 1&2 and IgG 1-4. Like 
memory T-cells, activated B-cells can also develop into long-lived memory B-cells that 
can be reactivated upon later re-exposure to its specific antigen. 
 
 
2.4 AUTOIMMUNITY 
Autoimmunity is defined as the immune system failing to recognize self-antigens as 
non-pathogenic, resulting in the development of an erroneous immune response to 
endogenous tissues and proteins [27]. The key cellular players in autoimmunity are 
TH1-cells, TC-cells, Treg cells and B-cells, but also iNKT cells and macrophages. In the 
circulation of healthy individuals, there are normally autoreactive T-cells and 
autoantibodies present, without causing disease [34]. However, autoimmunity and an 
autoimmune disease may develop if these cells are activated or the suppressive control 
over them is lost. Such a lack of suppression might be due to a lack of Treg cells or 
dysfunctional Treg cells, which can lead to uncontrolled T-cell activation and 
autoimmune diseases (e.g. [35, 36]). Studies have also shown that iNKT cells can 
inhibit autoimmunity through impairment of diabetogenic CD4 and CD8 T-cells in a 
mouse model for T1D [37]. 
 
The development of autoimmunity is dependent on both genetic factors and 
environmental factors, such as infectious agents, chemicals, drugs and smoking. There 
is a strong link between development of autoimmune disease and virus infections 
(reviewed in [38, 39].  Despite this link, a lack of microbial stimuli has also been 
suggested to be associated with an increased risk for developing autoimmunity; a 
phenomenon termed the ‘hygiene hypothesis’ [40].  
 
T1D is classically considered to be of autoimmune nature with the β-cells being 
destroyed by the immune system [41]. Supporting a role for autoimmunity in T1D 
development is the finding that autoantibodies towards β-cell antigens generally 
precedes actual T1D manifestation by several years [42]. It has also been demonstrated 
that autoreactive T-cells can be found in or around the islets of some, but not all, 
diabetic patients [43]. Although the involvement of autoimmunity and autoreactive T-
cells have been studied, the reason for triggering autoimmunity is less understood. 
 
2.5 VIRUSES 
Viruses are small, opportunistic and parasitic infectious agents without energy 
metabolism. Their life cycle relies solely on the host cells’ internal molecular 
machinery [44]. Hence, viruses are not actually “alive” according to the definition of 
life based on reproduction or replication and metabolism [45]. Despite not being alive, 
the virus’ ability to self-assemble has implications for the broad question of the origin 
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of life, as it supports an idea that life, as we know it, may have evolved from self-
assembling molecules. 
 
Viruses can infect various living organisms, from animals and plants to bacteria and 
archaea [44] and some viruses have a broad host range, infecting several different 
species and organisms. There are multiple different viruses and among these there are 
numerous serotypes, which in total, make viruses the most abundant biological entity 
on our planet [44, 46]. Viruses can also transfer genomic material between different 
organisms, making viruses key players in the evolution. When examining the human 
genome, several pseudogenes and introns have been discovered which all are due to 
viral genomic transfers. 
 
Antibiotics do not work on viruses and virus infections are generally not treatable. 
Some antiviral drugs exist, but these are used with caution and only for the most severe 
virus infections, to avoid viruses mutating to withstand the antiviral effects. Depending 
on which virus it is, these mutated functions may spread to other viruses through 
recombination. Most virus infections are cleared after being recognized by the adaptive 
immune system, through the activation of antiviral T-cells and production of 
neutralizing antibodies by activated B-cells. However, the only way to induce 
protective immunity against virus infections and reduce the risk of becoming infected is 
through the use of vaccines, as further discussed in chapter 4. 
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3 T1D ETIOLOGY 
Although the pathology of the selective destruction of the β-cells has been known for 
over a century, the etiology of T1D is still poorly understood. Clearly both genetic and 
environmental factors are involved in the development of disease, but how the two 
factors together regulate susceptibility, is still unknown. 
 
Several different models have been proposed to explain how, and why, the β-cells are 
destroyed. In a now classical model of T1D development and β-cell destruction, the 
most simplistic view of the disease is shown in Fig. 1A (modified from Eisenbarth 
[41]). As depicted, in genetically susceptible individuals a “precipitating event” 
initiates the β-cell destruction (linear), which then progresses until falling below a 
specific threshold of critical β-cell mass, when overt T1D is presented. This model has 
then been further refined, with added information regarding autoantibodies and a 
potential gradual dysregulation of autoreactive effector T-cells and regulatory T-cells, 
suggesting T1D to be a relapsing-remitting disease, as shown in Fig. 1B (modified from 
von Herrah et al.[35]). The β-cell mass in Fig. 1B is decreasing over time due to the 
suggested varying number of effector T-cells and regulatory T-cells, which at different 
points lead to an overt attack on the β-cells by autoreactive T-cells and development of 
autoantibodies. However the regulatory T-cells may thereafter recover control over the 
autoreactive T-cells, and the curve flattens out again. However, at a certain point, the 
disequilibrium reaches such a state that the regulatory T-cells completely loose their 
dampening effect over the autoreactive effector T-cells, resulting in T1D [35].  
 
 
Figure 1. Different models for the development of T1D. A. The classical T1D model 
suggested by Eisenbarth in 1986 (modified from [41]). B. The relapsing-remitting model 
suggested by von Herrath et al. in 2007 (modified from [35]). C. A model representing acute 
onset of T1D or fulminant T1D. D.  A combined model suggesting several triggering events, 
non-linear β-cell loss, induced autoimmunity and T1D development over time. 
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A third model for T1D development is shown in Fig. 1C, representing the quite rare 
form of T1D called fulminant diabetes which is characterized by a very rapid induction 
and destruction of the β-cells [47, 48]. It has been suggested that the development of 
fulminant diabetes could be the consequence of a virus infection in the β-cells which, 
upon recognition, rightfully should be killed by the immune system unfortunately also 
resulting in T1D development [47, 48].  
 
However, these models alone are not enough to explain the complex etiology of T1D. 
A combined model may account for several different triggering events, autoimmunity 
and β-cell loss, hence the suggested combination model presented in Fig. 1D. The 
curve representing β-cell mass in Fig. 1D is not solely dependent on dysregulation of 
effector T-cells and regulatory T-cells, but also accounts for environmental triggering 
events. Potentially, the initial triggering event is an infection that establishes 
persistency within the β-cells and further triggering events are reactivations of the virus 
or an infection with a related virus strain, resulting in exacerbated β-cell autoimmunity.  
 
3.1 GENETICS 
Numerous genetic factors involved in the etiology of T1D have been identified 
(recently reviewed in [49, 50]). Functional studies of these genes have also suggested 
different pathways involved in the development of T1D. The genes most commonly 
associated with T1D development are specific variants of the Human Leukocyte 
Antigen (HLA) class II, which encode the MHC-proteins involved in antigen 
presentation. The HLA combinations contributing to the highest risk for T1D 
development are the haplotypes HLA-DR3/DQ2 (HLA-DRB1 *03/DQA1*05:01- 
DQB1*02:01) and HLA- DR4/DQ8 (HLA-DRB1*04/DQA1*03-DQB1*03:02) [49, 
50]. The functions of other genes involved in regulating T1D susceptibility include 
regulation of immune responses, β-cell functions, insulin expression and recognition of 
virus infections [49, 50]. Interestingly, one gene identified through genome-wide 
association studies encodes for the MDA-5 protein, an intracellular sensor for viral 
RNA, potentially implicating a difference the response to certain viruses in people with 
T1D [51]. 
 
However, genetic factors cannot alone account the observed increase in incidence, as 
showed by the relatively low concordance rate for T1D development among 
monozygotic twins [52-54] and data suggesting that the increased T1D incidence is 
higher among individuals considered to have a low risk HLA genotype [55, 56]. Hence, 
the rise in T1D incidence reflects an environmental change that now, more than before, 
puts us at a higher risk for developing T1D. 
 
3.2 ENVIRONMENT 
In parallel with identified genetic factors, several environmental factors have also been 
suggested to regulate or trigger T1D development. Studies have suggested that dietary 
antigens [57-60], microbiotic alterations in the intestine [61-63] and virus infections 
[64-69] all can regulate susceptibility to T1D development.  
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Dietary antigens are basically anything we eat or drink. However, cow’s milk [57, 58], 
which contains bovine insulin, and the cereal protein gliadin [59], involved in celiac 
disease, have attracted specific interest. Due to the presence of bovine insulin in milk, 
children may develop antibodies to the bovine insulin if exposed to cow’s milk early in 
life [57, 58]. Induction of bovine-insulin immunity could then result in cross-reactive 
immunity toward human insulin and development of insulin-autoantibodies (IAAs), an 
early marker for the development of T1D [42]. Other studies indicated that dietary 
gluten could potentially trigger β-cell autoimmunity and diabetes development [59, 60]. 
Furthermore, dietary gluten/gliadin are antigens involved in celiac disease, an 
autoimmune disease that interestingly is more common among T1D patients than 
among healthy controls.  
 
Differences in the composition of the intestinal microbiota in diabetes-prone mice 
compared to diabetes-resistant mice have been described, where certain bacterial 
compositions can be either protective or causative of disease [61]. Similar differences 
were recently described for humans, where both a lack of bacterial diversity and a 
changed bacterial composition was observed in T1D patients compared to healthy 
controls [62]. Combining these observations with the findings that dietary antigens can 
affect T1D development suggests that the intestine represents an important site for 
numerous interactions between genes and environment, some of which may be 
involved in the etiology of T1D.  
 
Numerous studies have also linked virus infections to the development of T1D. 
Coxsackieviruses of serotype B (CVBs), members of the enterovirus (EV) genus, have 
specifically been implicated in T1D development (e.g. [64, 66-69]). However not 
investigated further in this thesis, rotavirus [65] and congenital rubella (reviewed in 
[70]) have also been suggested to have diabetogenic properties.  
 
3.3 COXSACKIEVIRUS SEROTYPE B AND T1D 
3.3.1 Background 
CVBs are small, non-enveloped single-stranded RNA viruses of the EV genus. 
Commonly, CVB infections only cause subclinical flu-like symptoms but on rare 
occasions, they can lead to severe diseases like poliomyelitis, myocarditis, aseptic 
meningitis, hepatitis and pancreatitis [44]. CVBs spread through the fecal-oral route, 
mainly infecting humans through ingestion of contaminated food and water.  
 
The primary site of replication for CVBs is in the intestinal mucosa [44], but what 
regulates virus spread from here is not known. CVBs can infect cells through the two 
main receptors Coxsackie and Adenovirus Receptor (CAR) [71] and Decay-
Accelerating Factor (DAF) [72]. CAR is a component of tight junctions, a cellular 
adhesion complex that tightly link one cell to another, for example in cardiomyocytes 
[73] and epithelial cells [74, 75]. DAF is a protein involved in regulating complement 
attachment on the cell surface [72]. The finding that CAR is expressed in tight 
junctions in IECs, but not exposed on the luminal side of epithelial cells, may suggest 
that infection of IECs is further regulated by other factors [76]. 
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Upon infection with CVBs, cells may recognize the infection and viral RNA through 
the pattern-recognition receptors MDA5 and TLR3 (reviewed in [77]). After binding to 
viral RNA, MDA5 initiates a signal cascade leading to the induction of type I IFN 
expression. This induced IFN production may thereafter activate several ISGs in the 
infected cell through paracrine signaling IFN signaling, but also signal to neighboring 
cells to enter an antiviral state [77]. The IFNs will also orchestrate and activate an 
immune response towards the virus. NK cells may be of importance in controlling the 
initial phase of infection, but upon activation of the adaptive immune response, TC-cells 
and antibody-producing B-cells are the key mediators of immunity (recently reviewed 
in [78]). 
 
3.3.2 CVBs and T1D 
There are several reasons for appointing EVs and CVBs a diabetogenic role. The first 
suggestion of CVBs being involved in the etiology of T1D was made in 1969, when 
Gamble et al. found that recent onset T1D patients were positive for CVB antibodies 
more frequently than healthy controls [64]. In 1979, Yoon et al. isolated CVB4 from a 
diabetic patient, and showed that this virus could induce diabetes in a mouse model 
[79]. Since then, several epidemiological studies have supported a causal link between 
EV infections in the development of T1D [80-83] and the role for EVs in the etiology 
of T1D was also recently highlighted by several systematic literature reviews and meta-
analyses [67-69]. Numerous studies have also detected EV RNA and/or EV proteins 
more frequently in pancreatic islets [84-87] and intestinal biopsies [88, 89] from T1D 
patients than in matching tissues from healthy individuals. It has also been suggested 
that EVs may cause a persistent infection in the intestinal mucosa, a finding that was 
suggested to be more common in T1D patients than in controls [88, 89]. A recent study 
further suggested that EV infections (non-sequenced) could accelerate the progression 
from islet autoimmunity to development of overt T1D [90]. However, most of the 
studies detecting EVs have not serotyped or sequenced their viral findings, hence it is 
difficult to know exactly which EV they actually have detected. 
 
Among all EVs, the CVBs have historically been appointed to be the most diabetogenic 
EV serotypes, with a special focus on CVB4 [64, 79, 85, 91]. CVBs have also been 
shown to be pancreatropic and capable of infecting human islets in vitro [84, 92]. 
Recently, two multi-center studies indicated that infections with CVB1 were 
specifically associated with development of β-cell autoimmunity in some children [83] 
and that CVB1 infections were more common in children who developed T1D [93]. 
These studies clearly indicate a role for a specific virus in the etiology of T1D, 
however, they do not present a clear mechanism to explain how CVB1 infections are 
involved in T1D development. 
 
3.3.3 The poliovirus hypothesis 
There is a marked difference in T1D incidence world wide, with clear differences 
observed in different parts of the world, but also in neighboring countries [11-16]. 
Based on the increasing amount of circumstantial evidence for a link between EV 
infections and T1D development, the incidence of T1D should be high in countries 
with a high prevalence of observed EV infections, and vice versa. However, the 
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opposite has been observed in epidemiological studies conducted in different 
geographical regions of Europe, where the frequency of observed EV infections 
showed an inverse correlation to the incidence of T1D [13, 94, 95].  
 
A parallel for this counter-intuitive observation has however been described earlier for 
poliovirus (PV) infections and the development of paralytic poliomyelitis [96]. Before 
the 20th century, PV infections were endemic but the number of poliomyelitis cases was 
low. With improved hygienic standards and public sanitation from the late 19th century, 
the prevalence of PV infections decreased, but surprisingly, the number of infant 
poliomyelitis cases increased dramatically. A suggested explanation for this 
phenomenon was the decline in herd immunity in parallel with the decreasing 
prevalence of PV infections in the population [96]. The reduced herd immunity would 
further have affected young children via the reduced transfer of protective maternal 
antibodies and also since children would have encountered PV later in life, when 
maternal antibodies had waned. Thus, the lack of protective maternally transferred 
antibodies combined with a later exposure to PV allowed the virus to spread more 
vigorously, resulting in severe tissue damage and poliomyelitis in some susceptible 
individuals.   
 
In 2000, Viskari et al. applied the poliovirus hypothesis on EV infections and T1D 
development in an attempt to explain the high incidence of T1D in countries with a low 
number of observed EV infections [97]. Hence, the ‘extended’ poliovirus hypothesis 
states that a low frequency of EV infections in the background population can increase 
the risk for severe complications in infected genetically susceptible individuals, such as 
β-cell damage and T1D development [97]. The heightened risk for T1D development is 
in this model explained by the reduced level of maternally transferred antibodies and/or 
by children being exposed to diabetogenic EVs later in life, when the protective 
maternal antibody effect has waned [97-100]. We recently published direct evidence 
for the extended poliovirus hypothesis applied on EV infections and T1D in a mouse 
model for virus-induced diabetes ([101], Paper III). It has also been suggested that the 
immunity obtained if encountering a pathogen under the protection of maternal 
antibodies can persist up to adulthood [102].  Indirect evidence for the extended 
poliovirus hypothesis have also been shown in human studies, where high maternal 
titers of EV-specific antibodies in serum and breast milk correlated with reduced 
frequency of such EV infections in children [103]. 
 
3.4 VIRUSES AND T1D: DIRECT INFECTION 
One way viruses may cause diabetes is through a direct infection of the β-cells. In this 
scenario, the immune system may attack and kill the infected β-cells, which will not 
only results in viral clearance but also T1D development. In this case T1D is not an 
autoimmune disease, but rather caused by the virus infection alone. This may be the 
case for fulminant diabetes, which has a very fast onset, or reflect a persistent infection, 
which may be reactivated until all β-cells are destroyed. 
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3.5 VIRUSES AND T1D: MOLECULAR MIMICRY 
Another way through which viruses may cause T1D is via autoimmunity and molecular 
mimicry. This basically means that an immunogenic epitope of a virus (i.e. a part of a 
virus protein which the immune system can react to) has sequence similarities with a 
part of an endogenous host protein, and thereby a cross-activation of the immune 
system can occur [38, 104]. The result leads to a correct immune response towards the 
viral antigen by T- and B-cells, but unfortunately also to an autoimmune response 
towards the self-antigens, due to cross-reactivity, i.e. molecular mimicry [38, 104].  
 
In the respect of autoimmune T1D and virus infections, it is interesting that the non-
structural viral 2C protein of CVB4 has been suggested to have a shared epitope with 
the host proteins glutamate decarboxylase (GAD) -65 and -67 [105-107]. GAD 
autoantibodies have also been shown to be present before T1D onset in humans and 
proposed as an autoantigen in T1D development (e.g. [5, 49, 108, 109].  
 
3.6 VIRUSES AND T1D: BYSTANDER ACTIVATION 
A third way viruses may be involved in T1D development is through autoimmunity via 
bystander activation. This implies an unspecific activation of mainly autoreactive T-
cells by activated APCs [38]. This can occur after infection, when highly activated 
APCs are presenting antigens to specifically activate antiviral TC-cells through TCR-
dependent interactions. However, surrounding autoreactive T-cells may potentially also 
be activated through TCR-independent pathways, due to released inflammatory 
cytokines. The activated antiviral T-cells killing infected cells may also further trigger 
bystander activation due to the release of inflammatory cytokines and autoantigens at 
the site of infection [38]. 
 
Bystander activation and autoimmunity is of interest for T1D and CVBs, since CVBs 
have been found to be pancreatropic [84]. Using a mouse model of autoimmune 
diabetes, the non-obese diabetes (NOD) mouse, several studies have shown that the 
exocrine cells in the pancreas are destroyed soon after CVB infections, but the islets are 
spared [110, 111], presented in Fig 2A and B ([112] and P. Larsson, V. Stone et al., 
unpublished results). Other studies have also showed that, depending on the time of 
infection, CVB infections can accelerate T1D development in NOD mice [113, 114]. 
This acceleration has been suggested to depend on bystander activation by the antiviral 
TC-cells, which are killing the infected pancreatic exocrine tissue. A combination of 
secreted or cell-bound co-stimulatory molecules in the inflammatory milieu may 
activate surrounding islet-specific autoreactive T-cells to attack and kill the islets [38], 
as shown in Fig. 2C and D ([112] and P. Larsson, V. Stone et al., unpublished results). 
Further, persistent infections may also cause autoimmunity, through the constant 
presence of viral antigens, which may drive an immune response to keep a constant 
inflammatory process active at the site of infection [38]. 
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Figure 2. Insulin-stained islets after CVB4 infection of female Proins-/- NOD mice. A, B. 
Destroyed exocrine tissue but spared and healthy islets in a pancreas from a 6-week old mouse 
infected with CVB4, day 7 post infection. C, D. Completely destroyed exocrine tissue and 
destroyed islets in a pancreas from a 6-week old mouse infected with CVB4, day 7 post 
infection. IHC stainings for insulin with insulin-positive cells stained in brown ([112] and P. 
Larsson, V. Stone et al., unpublished results). 
A B C D 
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4 VACCINES 
The only way to induce protective immunity against virus infections is through the use 
of vaccines [100]. Unlike bacterial infections, virus infections cannot be treated with 
antibiotics, a common misunderstanding among the general population. In fact, most 
virus infections cannot be treated at all but only prevented through vaccination and 
sanitation. Today, the use of vaccines have eradicated the deadly Variola virus that 
causes smallpox and poliovirus is very close to being eradicated. The use of child 
vaccination programs has also significantly reduced the number of pertussis and 
diphtheria cases in children. 
 
4.1 HISTORY 
The first modern vaccine was developed by Edward Jenner in 1796, who showed that 
the pus from cowpox blisters could confer protection against the deadly smallpox virus 
[115]. Despite earlier notions of the use of ‘variolation’ to induce immunity towards 
smallpox exist, Jenner is generally considered to be the first to have showed that the 
obtained immunity from cowpox and cowpox blister pus protected individuals against 
smallpox infection [115]. 
 
Later, vaccines against numerous viruses and bacteria have been developed which have 
lead to improved general health and a reduced infectious burden for the general 
population. In addition to Jenner, other front figures in vaccine development were: 
Louis Pasteur (developed vaccines against anthrax and rabies), Jonas Salk and Albert 
Sabin (developed the first inactivated and oral poliovirus vaccine, respectively) and 
Maurice Hilleman (responsible for developing vaccines against measles, mumps, 
hepatitis A& B and chickenpox). Recently, vaccination campaigns have also been 
introduced against human papillomavirus (HPV), a virus that can cause cervical cancer. 
Additionally, vaccination against the seasonal influenza virus is usually offered to 
individuals in risk groups every year. 
 
4.2 HOW DOES A VACCINE WORK? 
The idea of vaccination is to induce an immunogenic response and immunity towards a 
dangerous pathogen in a safe setting [100]. This is achieved through priming of the 
immune system using non-infectious antigens, like inactivated whole pathogens, viral 
or bacterial proteins or toxins. Attenuated (weakened and less virulent) viruses are also 
used, since they are cheap and provide a good immune response without the need for 
adjuvants or booster injections. However, there is a risk of attenuated viruses reverting 
to virulent forms through mutagenesis, as seen occasionally in some cases after oral 
poliovirus vaccination [116].   
 
Upon vaccination, the host’s immune response recognizes the foreign or immunogenic 
substance, which activates both the innate and adaptive immune system and their 
respective cellular components. This basically results in activated APCs, T- and B-
cells, which leads to antibody production and generation of long-lived memory T-, and 
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B-cells, for a faster secondary response upon reactivation. The antibodies produced by 
the B-cells can thereafter neutralize the pathogen if the host would encounter it. 
 
4.3 ADJUVANTS 
For some antigens, the immune response needs to be boosted in order to be properly 
activated. Such a boosting effect is achieved through the use of adjuvants in the 
vaccine, which functions as unspecific activators of the immune system. Examples of 
adjuvants are bacterial toxins, aluminum hydroxide (alum), squalene, thimerosal, 
mineral oil and oil-water emulsions like AS03. Alum is commonly used in human 
vaccines today, for example in diphtheria-tetanus-pertussis, human papillomavirus and 
hepatitis vaccines. 
 
4.4 SAFETY CONCERNS 
The use of vaccines and adjuvants has however been questioned and debated from time 
to time. In the now infamous article published in 1998 by Wakefield et al., the authors 
reported an observed link between the vaccine used against measles, mumps and 
rubella and development of autism, in some children [117]. Despite the fact that this 
study was retracted, in part by ten out of twelve authors [118] and then completely 
retracted by the journal due to scientific irregularities and fraud [119], this article is still 
causing public disbelief in vaccines, resulting in parents denying vaccinations for their 
children.  
 
Another debate about vaccine-related disease was spurred after vaccinations against the 
potential pandemic influenza A H1N1 virus in 2009-2010. In some European countries 
with high vaccine coverage, there was a marked increase in the number of narcolepsy 
cases developing after vaccination using the Pandemrix vaccine, an AS03-adjuvanted 
H1N1 vaccine [120-123]. Initially the vaccine was accused for causing the observed 
increase in narcolepy, and the use of AS03 as an adjuvant for influenza A vaccination 
was debated [124]. However, prior to the observed increase in narcolepsy after H1N1 
vaccinations, a seasonal difference in the development of narcolepsy that followed the 
influenza A infection peaks was observed in China [123, 125]. Further, it was also 
noted that there was a clear peak of narcolepsy cases in H1N1 infected individuals in 
China [123, 125]. This suggested that the influenza A virus itself, especially the H1N1 
strain, could cause narcolepsy since these patients were not vaccinated [123, 125]. All 
these findings were however recently explained in a study demonstrating that 
narcolepsy is indeed an autoimmune disease which can be caused by molecular 
mimicry, with an autoimmune T-cell epitope shared by the neuropeptide hypocretin 
and the H1N1 virus, specifically affecting genetically susceptible individuals [126]. 
Hence, in these susceptible individuals, both the H1N1 virus and the H1N1 vaccine 
combined with a potent adjuvant, appear to be able to trigger narcolepsy [126]. In the 
US, non-adjuvanted H1N1 vaccines were used and there was no increase in the number 
of narcolepsy cases, hence it remains to be determined if the use of a less potent 
adjuvant than the AS03 would have affected the development of narcolepsy observed 
in some European countries [126]. 
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When developing a vaccine there are rigorous safety concerns involved, since a vaccine 
has to demonstrate a good immunogenic profile without causing side effects. As 
mentioned in the example above, there might be specific gene-virus/vaccine 
interactions causing autoimmunity that are very rare, which means that they might not 
be noticed in small studies. This is especially important if developing a vaccine against 
a virus associated with development of autoimmunity, since the vaccine itself must be 
shown to be safe in an autoimmune setting. Unfortunately, rare side effects are often 
impossible to predict, but the function and potential side effects must be meticulously 
tested prior to releasing novel vaccines to the public, in order to avoid issues of public 
disbelief in vaccines.  
 
Over the years, vaccines have saved, and are continuously saving, countless of lives. 
The high level of herd immunity provided by thorough vaccination programs is key to 
reduce spread of pathogens and to protect genetically susceptible individuals from 
detrimental infections.  
 
4.5 VACCINATION PROGRAMS 
The current Swedish vaccination program for children born after 2009 is depicted in 
Table 1 (modified from [127]). As shown, boys receive a total of ten shots whereas 
girls receive thirteen, due to the three extra shots of HPV vaccine to reduce the risk for 
developing cervical cancer [127]. In addition to this broad vaccination program, 
children at risk are also offered hepatitis B vaccinations and the BCG vaccine against 
tuberculosis [127]. 
 
 
Table 1. The current Swedish vaccination program (2014), modified from [127]. 
 
 
        
 
 
4.6 DEVELOPMENT OF NEW VACCINES 
Although numerous vaccines exist, there are still many communicable diseases for 
which we lack functional vaccines. However not fatal, a classic example for a disease 
caused by viruses is the common cold, which can be caused by numerous different 
viruses and combinations of these, for which we lack vaccines and functional 
The$Swedish$vaccination$program$for$children$born$after$2009:
Age: Vaccine:
3$months Diphteria,$tetanus,$pertussis,$polio$&$Haemophilus$influenzae,$type$b
3$months Pneumococci
5$months Diphteria,$tetanus,$pertussis,$polio$&$Haemophilus$influenzae,$type$b
5$months Pneumococci
12$months Diphteria,$tetanus,$pertussis,$polio$&$Haemophilus$influenzae,$type$b
12$months Pneumococci
18$months Measels,$mumps$&$rubella
5H6$years Diphteria,$tetanus,$pertussis$&$polio
6H8$years Measels,$mumps$&$rubella
11H13$years HPV$(girls$only,$3$injections)
14H16$years Diphteria,$tetanus$&$pertussis
  20 
treatments except symptomatic treatments [128]. More severe diseases for which we 
lack vaccines include human immunodeficiency virus (HIV), hepatitis C, dengue virus 
and, among children, respiratory syncytial virus (RSV). Due to the high mutation rate 
of surface antigens on influenza A viruses, new vaccines have to be developed every 
year since one vaccine cannot cover all different combinations of influenza A surface 
antigens. 
 
One should note that the above chapters regarding vaccines have focused on antiviral 
vaccines. There are several non-viral disease for which we also lack vaccines, many of 
them being of parasitic nature. Examples of non-viral disease for which we lack 
vaccines include malaria, hookworms and leishmania, which cause countless of 
infections and deaths every year. 
 
4.7 MATERNAL ANTIBODIES 
4.7.1 Transfer of protection 
Due to the immature immune system of newborn babies, they do not respond to 
vaccinations [99, 129]. This is the reason why babies are generally not vaccinated 
before the age of three months. This may provide a window of opportunity for certain 
pathogens, to which children will be vaccinated against later on, to infect. 
This risk of may be reduced by the passive antibody protection mediated from the 
mother [99, 103]. The two antibody isoforms capable of transferring maternal 
protection are IgGs, which are transferred over the placental barrier during pregnancy, 
and IgAs, which are transferred via the breast milk.  
 
However not yet recommended in Sweden, the Centers for Disease Control and 
Prevention (CDC) in the USA now recommend pregnant women to receive a booster 
vaccination against tetanus, diphtheria and pertussis (a vaccine combination known as 
Tdap) during gestation week 27-36 [130]. This booster injection may maximize the 
maternal immune response towards these pathogens and also the transfer of maternal 
antibodies to the fetus [130]. The National Health Service (NHS) in the UK also 
mentions that a booster of pertussis vaccine in pregnant women could reduce the risk 
for pertussis in infants, however the NHS has not officially recommended vaccinations 
for pregnant women [131]. Since no single pertussis vaccine is used, the NHS 
suggestion is to receive a combination vaccine against tetanus, diphtheria, pertussis and 
polio [131]. Indeed, vaccination of pregnant women is an interesting vaccine strategy to 
provide children with protection already from birth. 
 
In the context of CVBs infecting children, it has been shown that many children 
encounter a primary infection before the age of 3 months [132], which is within the 
time frame where maternal antibodies, if present, can protect the child from infections 
[99, 103]. Some studies, but not all, have also found a significant protection against β-
cell autoimmunity and T1D development in children that are breast fed longer [59, 
133].  
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4.7.2 Transfer of disease 
Antibodies transferred from the mother to the fetus can also be pathogenic in some 
cases. A classic example of detrimental antibodies transferred from mother to fetus is 
the transfer of anti-Rh antibodies from an Rh- mother to an Rh+ fetus, if the mother has 
previously given birth to an Rh+ sibling [27]. Anti-Rh antibodies that cross the 
placental barrier can cause a severe hemolytic disease called erythroblastosis fetalis, 
destroying the fetal red blood cells leading anemia, ranging from mild to fatal [27]. 
Destruction of the red blood cells causes conversion of hemoglobin to bilirubin which 
can lead to brain damage in the fetus, due to the accumulation of bilirubin in the brain 
[27].  
 
Other examples of diseases transferred from mother to child depending on antibodies 
are Sjögrens syndrome, systemic lupus erythematosus (SLE) and Grave’s disease. 
Pregnant women with rheumatic diseases like Sjögrens syndrome or SLE risk 
transferring antibodies to the fetus that can results in severe fetal heart block [134, 135].  
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5 AIMS OF THIS THESIS 
The overall aim of this thesis was to expand our current knowledge on how and if 
CVBs may be involved in regulating T1D development. The four papers included here 
were all based on individual hypotheses, but they all resulted in new knowledge 
regarding the effects CVBs may have on T1D development and suggesting new 
strategies for how this may be counteracted. 
 
 
Specific aims: 
 
• To determine which cellular components are involved in regulating diabetes 
development in diabetes-prone mice after CVB4 infections. (Paper I). 
 
• To describe the mechanism for the protective effect by αGC against CVB4-
accelerated diabetes development in diabetes-prone mice. (Paper I). 
 
• To test the efficacy and safety of a novel CVB1-specific vaccine in mice. 
(Paper II). 
 
• To study the effects on autoimmunity and diabetes development by CVB1 and a 
novel CVB1 vaccine in diabetes-prone NOD mice. (Paper II). 
 
• To test if maternal antibodies can protect genetically susceptible offspring 
against CVB3 infection and CVB3-induced diabetes in a mouse model for 
virus-induced diabetes. (Paper III). 
 
• To evaluate how human intestinal epithelial cells (IECs) respond to IFN-λs in 
respect to inducing an antiviral state. (Paper IV). 
 
• To determine if the two IEC lines CaCo-2 and HT-29 express the two main 
receptors used by CVBs for cellular entry, CAR and DAF (Paper IV). 
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6 REFLECTIONS ON MATERIAL, METHODS AND 
RESEARCH DESIGN 
In this chapter I will discuss the research design, material and methods that I have used 
in Paper I-IV. I will also reflect on technical difficulties I have encountered and how 
some methods had to be developed further in order to fully work in our experimental 
setup. 
 
6.1 CELL LINES 
Throughout the studies included in this thesis, several different cell lines have been 
used. For culturing details and medium compositions, please see the material and 
methods sections in Paper I-IV.  
 
HeLa, GMK and Vero cells were used for virus propagations, titrations and titrations of 
neutralizing antibodies in Paper I-IV. The human colonic epithelial cell lines CaCo-2 
and HT-29 were used to study the effect of IFN-λs on IECs in Paper III. 
 
6.2 VIRUSES 
In total four different strains of CVBs were used in the studies described in this thesis. 
The original stocks of CVB3 Nancy and CVB4 E2 were kindly provided by Dr Gun 
Frisk (Uppsala University, Sweden). A plasmid encoding the CVB3-eGFP virus was 
kindly provided by Professor Lindsay Whitton (The Scripps Research Institute, USA). 
The CVB1Nm strain was provided by Sanofi Pasteur (France). 
 
CVB3 Nancy, CVB3-eGFP and CVB4 E2 were propagated and titrated using HeLa 
cells. Titrations were done a standard plaque assay in 6-well plates. 
 
The CVB1Nm strain was propagated and titrated in Vero cells. Titrations were done 
using the CCID50 end-point dilution method, and titers were calculated according to the 
Reed and Muench formula [136]. However, some titrations were also done by real-time 
PCR, as described in material and methods in Paper II. 
 
Our initial idea for Paper III was to use an oral infection model to mimic the natural 
route of infection, but the low reproducibility in obtaining systemic viral spread and the 
need for high, and biologically non-relevant, concentrations of virus in our pilot 
experiments forced us to use i.p. infections throughout the study. This resulted in the 
use of i.p. infections for all infected mice included in Paper I-III. 
 
6.3 VACCINE 
The prototype CVB1 vaccine used in Paper II was developed by Vactech Oy (Finland) 
and Sanofi Pasteur (France). CVB1Nm stocks were propagated in Vero cells and then 
purified using a two-step centrifugation and the use of a 13% sucrose cushion. Purified 
virus stocks were then inactivated in PBS supplemented with 0.1% Tween80 and 
0.025% formaldehyde for 72h at 37°C. Complete inactivation of the virus stocks were 
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monitored using Vero cells and CCID50 end-point titrations, according to the Reed & 
Muench formula [136].  
 
Due to the successful immunizations using the formalin-inactivated poliovirus vaccine 
without adjuvants [137], the prototype CVB1 vaccine used here also non-adjuvanted. 
Pilot studies in BALB/c mice showed good immunogenic properties by the vaccine 
(data not shown), hence all further vaccinations were done using a non-adjuvanted 
vaccine and a dose of 106 CCID50 equivalents of CVB1, that was injected sub 
cutaneously intra scapular (i.s.). 
 
6.4 NEUTRALIZATION ASSAY 
There are several different methods to titrate the concentration of antibodies in serum: 
end-point dilution curves (CCID50 titrations), plaque-neutralization assays or flow 
cytometry. Due to the lack of an established protocol in our lab, one initial 
experimental challenge we had was to set up a functional neutralization assay.  
 
Initial attempts were done to set up a fast and reliable method of detecting neutralizing 
antibodies based on flow cytometry, with the hypothesis that this method would allow 
for a higher throughput than the traditional CCID50 titrations and plaque-reduction 
assays. The method was based on a simple protocol where serial diluted serum was 
incubated with a pre-defined amount of CVB3 or the GFP-encoding CVB3-eGFP 
before the mixture was added to a specific number of HeLa cells. The blocking of virus 
replication would then be compared to freely infected cells using flow cytometry to 
measure GFP fluorescence or other fluorescent secondary antibodies used to detect 
cells stained intracellular for the viral VP1-protein. However, this technique proved to 
be harder to use than initially thought, and after several failed attempts to improve the 
method and detection, we decided to change to another method. 
 
The CCID50 end-point dilution method is used in many different laboratories. The 
sensitivity and reproducibility of the assay is indeed dependent on perfect cell growth, 
most commonly tested in 96-well plates. After failed attempts to use this high-
throughput titration assay with HeLa cells, we decided to abandon even this model and 
resort to adopting a previously established protocol for a standard plaque-reduction 
assay in order to detect and titrate neutralizing antibodies in serum samples. Despite 
being a slower method, the reproducibility and sensitivity of this assay was deemed 
higher than both the other methods. 
 
After initiating collaboration with the lab of Professor Heikki Hyöty (University of 
Tampere, Finland), we adopted their protocol for a plaque-neutralization assay and I set 
up this assay in our lab. Using their protocol as a basis, but with HeLa cells and human 
serum previously confirmed to contain neutralizing antibodies against CVB3, I 
developed a protocol for testing different viruses and antibodies, which is now widely 
used in our group for titration on neutralizing antibodies. The final protocol for the 
method is stated in the material and method section in Paper III. 
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Titrations of antibodies against CVB1 were also done using a plaque-neutralization 
assay, but here with GMK cells instead of HeLa cells. The slightly different protocol 
used for these titrations is presented in the material and method section in Paper II. 
 
6.5 ANIMAL HUSBANDRY 
The use of research animals is somewhat ethically controversial. However, it provides 
immunologists with an invaluable tool for studying immune responses in complex 
whole organisms. Hence, to study how the immune system responds to potentially 
diabetogenic virus infection, research animals are needed.  
 
All animals included in Papers I-IV were housed in specific pathogen-free 
environments in approved facilities and all experiments were approved by local ethic 
committees and carried out according to Swedish and French law. For additional detail 
regarding individual experiments, please see the material and methods section in 
Papers I-IV. 
 
6.5.1 Non-obese-diabetic (NOD) mice 
The NOD mouse model dates back to the early 1980’s, when Makino et al. published 
their first study on a mouse model for autoimmune diabetes [138]. NOD mice develop 
spontaneous autoimmune diabetes from around 10 weeks of age. Hallmarks of diabetes 
development in the NOD mice are insulitis, autoantibodies against β-cell antigens and a 
T- and B-cell dependent autoimmune etiology. Apart from the clearly displayed 
insulitis, all of these hallmarks are also observed in human T1D development. There is 
a clear sex-dependent difference in diabetes development among NOD mice, with 
approximately 60-80% of the females developing diabetes but only 20-30% of the 
males. Hence female NOD mice are used in most studies. The diabetes incidence in 
NOD mice is also dependent on animal housing standards, where a less clean animal 
house might provide a lower incidence of diabetes. The NOD mouse model is the most 
used model for studying autoimmune diabetes.  
 
NOD mice were used in Papers I-III for evaluating diabetes development in different 
settings. For Paper III, NOD mice were also used to determine autoimmune safety of a 
prototype CVB1 vaccine and potential induction of autoimmunity after CVB1Nm 
infection and vaccination using formalin-inactivated CVB1Nm.  
 
6.5.2 Proinsulin 2–deficient NOD mice 
For the studies conducted in Paper I, we took advantage of the genetically modified 
Proins2-/- NOD mice, which lack the gene encoding for proinsulin-2. Due to the lack of 
proinsulin-2-presentation to T-cells in the thymus during T-cell development, these 
mice develop autoimmune diabetes with an accelerated onset compared to the normal 
NOD mice [139]. Generally, the Proins-/- NOD mice develop diabetes around 6-8 
weeks of age [139]. Like in NOD mice, diabetes development is preceded by islet 
autoimmunity and insulitis [139]. The use of Proins-/- NOD mice significantly 
shortened the duration of the experiments conducted in Paper I. 
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6.5.3  Vα14 transgenic NOD mice 
In Paper I, we also used transgenic NOD mice expressing the invariant T-cell receptor 
α-chain Vα14-Jα18 (Vα14-NOD). As previously shown, these mice have an increased 
frequency of iNKT cells that can regulate diabetes development in the NOD mouse 
[22].  
 
Vα14-NOD and Proins2-/- NOD mice were also crossed in order to obtain Vα14 
Proins2-/- NOD. These mice were used to study iNKT cells isolated from murine 
pancreatic islets and their response to CVB4 and αGalCer in Paper I. 
 
6.5.4 BDC2.5 Cα-/- transgenic NOD mice 
The CD4 T-cells from the TCR transgenic BDC2.5 Cα-/- NOD (BDC2.5 Cα-/- NOD) 
have been shown to be islet specific and have diabetogenic properties [140]. To study 
the effect of suppressive macrophages on diabetogenic T-cells in Paper I, we isolated 
T-cells from BDC2.5 Cα-/- NOD mice and co-cultured them with pancreatic 
macrophages from αGalCer and αGalCer+CVB4 treated Proins2-/- NOD mice in a T-
cell proliferation assay. 
 
6.5.5 Socs-1 transgenic NOD mice 
In Paper III we used Socs-1 transgenic NOD (Socs-1 tg) mice as a model for CVB-
induced diabetes [110, 111, 141, 142]. The Socs-1 tg mice express the Suppressor-of-
Cytokine-Signaling (Socs) 1 protein under the control of a human insulin promotor, 
which specifically renders their β-cells unable to respond to IFN signaling. Upon a 
systemic CVB infection that spreads to the pancreas, Socs-1 tg mice develop diabetes 
within 5-11 days post infection, due to the failing interferon-induced antiviral defense 
in the β-cells [110, 111]. 
 
Heterozygous Socs-1-tg mice were bred with wild-type NOD mice, rendering ~50% of 
the offspring carrying the Socs-1 gene. DNA screening for the presence of Socs-1 was 
done by PCR on tail or ear biopsies from all mice. The detailed generation and breeding 
of Socs-1 tg mice have been described previously [110, 111, 141, 142]. 
 
I carried out the initial titrations of CVB3 Nancy, CVB4 E2 and CVB1Nm in order to 
obtain a systemic infection resulting in diabetes development in i.p. infected Socs-1 tg 
mice. 
 
6.5.6 BALB/c mice 
In Paper II we used BALB/c mice for the initial vaccinations and CVB1 infections. 
The BALB/c strain was used as a model of a non-diabetic and non-autoimmune 
‘standard mouse’. BALB/c mice are also generally susceptible to infections, hence a 
good model to use for vaccine studies.  
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6.6 FLOW CYTOMETRY 
In order to study the individual cellular components of the immune system in Paper I, 
we used flow cytometry and fluorescence-activated cell sorting (FACS). Using primary 
cells from mice, this allowed us to look for specific cells and their activity depending 
on different treatments. Single cells from murine pancreatic islets were prepared after 
CVB4 infection and stained with antibodies to distinguish between different immune 
cells. Cells were stained using the following surface antibodies: CD45, CD11b, CD11c, 
Ly-6G, Ly6C, F4/80, 120G8, CD115, CD62L, CD4 and CD8. αGalCer-loaded CD1d 
tetramers were also used to identify iNKT cells. Intracellular stainings were also done 
for Ki-67 and cytokines IL-4, IL-13 and IFN-γ. Non-specific Fc binding was blocked 
by an anti CD16/CD32 antibody. Staining details and protocol is presented in the 
material and methods of Paper I. 
 
We also used flow cytometry in Paper IV in order to detect surface expression of the 
two main receptors used by CVBs for cellular entry, CAR and DAF, on the human IEC 
lines CaCo-2 and HT-29. Primary antibodies against CAR and DAF were after staining 
visualized using a secondary antibody for CAR and streptavidin-conjugated APC to 
detect the biotinylated DAF antibody. 
 
All flow cytometry experiments were conducted using a BD Fortessa or BD Acurri C6 
flow cytometer or sorted using a BD FACSAria II. 
 
6.7 IN SITU HYBRIDIZATION (ISH) 
In Paper I we performed in situ hybridization (ISH) in order to detect viral RNA in 
tissues harvested from mice after infection. The protocol used for the in situ 
hybridization has been published previously [88, 89, 143], and was here used with 
some modifications. Sections were counterstained using Kernechtrot, Light green or 
Hematoxylin and after dehydration in 100% EtOH, a dehydration step in xylene was 
skipped and cover glasses were mounted using 90% glycerol in PBS. Using ISH in 
Paper I, we tried to detect infected islets in the pancreas of CVB4 infected mice. 
However, we could not detect any infected islets in the pancreata from CVB4 infected 
mice at any time point.  
 
We also used ISH in Paper II to detect infected pancreata after CVB1 infection 
(supplementary figure 1A-C in Paper II). 
 
During the staining process using ISH, I made an attempt to further improve the 
protocol by changing the counterstaining used. Background stainings using Kernechtrot 
provides good contrast to the blue precipitate from NBT/BCIP, but the resolution of the 
pancreas in general was not ideal. A change to Light green improved the resolution and 
visibility of the pancreatic morphology, however, this was further improved by using 
hematoxylin for counterstaining. The resolution of the organ morphology was indeed 
much improved, but the blue color provided by hematoxylin counterstaining made 
detection of viral RNA using NBT/BCIP somewhat harder to visualize. We are 
currently still working on technical improvements of the ISH protocol in order to 
improve detection of viral RNA in pancreatic sections. 
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6.8 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
When analyzing organ morphology after infection, all pancreata were fixed in formalin 
prior to sectioning and hematoxylin and eosin staining (H&E). H&E stainings were 
used specifically to monitor pancreatic destruction and morphology after CVB 
infections. 
 
Further, we have also performed immunohistochemistry (IHC) to stain pancreata using 
insulin and glucagon antibodies, to find islets (Fig. 2 in Paper III and Supplementary 
figure 1 in Paper II). The combination of insulin and glucagon staining in consecutive 
sections allowed us to find islets that did not produce insulin, which may have been 
affected by a virus infection. 
 
The protocols for preparing tissue sections and stainings have been previously 
described [144]. The analysis of all stained tissue sections were conducted blinded by 
two independent observers, as previously described [110]. 
 
6.9 INSULIN AUTOANTIBODY (IAA) TITRATIONS 
We titrated IAA concentrations in serum samples saved from mice before and after 
treatments in Paper II. IAA levels were quantified using a previously established 
radiolabel-binding assay [145]. After standardization, the cut-off limit for IAA 
positivity was set to 0.881 relative units. Using the cut-off value we could compare 
both the actual titers of IAAs and the frequency of seroconverting mice after each 
treatment (Fig. 4A-C in Paper II). 
 
6.10 SERUM TRANSFERS 
In Paper III we conducted adoptive serum transfers of heat-inactivated confirmed 
antibody-positive and negative sera from NOD mice to naïve Socs-1 tg mice. Serum 
(400µl/mouse) was injected i.p. to recipient mice and presence of neutralizing 
antibodies in serum was assessed 24h post transfer.  
 
6.11 QUANTITATIVE REAL-TIME PCR 
We have used quantitative real-time PCR (qRT-PCR) to detect expression levels of 
different genes in Paper I and IV, and we used qRT-PCR to detect virus in Paper II. 
Please see material and methods section of Papers I, II and IV for detailed protocols on 
genes tested, primers used and PCR machines used for analysis. 
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7 RESULTS AND DISCUSSION 
7.1 Paper I  
Protection Against Type 1 Diabetes upon Coxsackievirus B4 Infection and iNKT 
Cell Stimulation: Role of Suppressive Macrophages  
 
T1D may result from an attack by autoreactive T-cells on the insulin-producing β-cells. 
Despite the fact that several genetic and environmental factors have been identified and 
suggested to regulate susceptibility to disease, T1D etiology remains elusive [5, 49]. 
Enterovirus infections, especially by CVBs, have been linked to T1D development [64, 
79, 85, 146]. Depending on the timing of infection, CVB4 infection can accelerate 
diabetes development in NOD mice [91, 113]. However, protection from diabetes 
development has also been observed after virus infections in NOD mice. Previous 
studies suggested that protection from diabetes development in diabetes-prone mice 
infected with lymphocytic choriomeningitis virus (LCMV) was mediated by iNKT 
cells, which promoted antiviral CD8 T-cell responses but still protected the islets from 
autoreactive CD8 T-cells [147, 148]. iNKT cells can be activated and stimulated by the 
ligand αGC, and it has been shown that diabetes an be prevented in diabetes-prone 
mice by increased numbers of αGC-stimulated iNKT cells [22, 149, 150]. Despite their 
suppressive role diabetes development, iNKT cells also have potent immunmodulatory 
functions in enhancing the immune response towards different pathogens [151, 152]. 
We were therefore interested in evaluating iNKT cell responses to CVB4 and 
determine the role for iNKT cells in regulating diabetes development in CVB4-infected 
diabetes-prone mice. 
 
We first confirmed the previous finding that CVB4 could accelerate diabetes onset 
[113] and compared diabetes development among untreated, αGC-treated, CVB4 
infected and combined αGC-treated and CVB4 infected NOD and Proins-/- NOD mice 
(Fig. 1A-D in Paper I). Proins-/- NOD mice were used due to their accelerated diabetes 
onset compared to NOD mice [139]. As expected, CVB4 infected mice had an 
accelerated diabetes onset and αGC-treatment alone had no effect on diabetes 
development. However, mice treated with αGC and CVB4 had a significantly lower 
incidence of diabetes. There was no difference in pancreatic virus titers after CVB4 
infection with our without αGC-treatment (Fig. 1F in Paper I). ISH also showed similar 
levels of virus in the exocrine tissue of the pancreas and no virus in the islets from 
CVB4 infected Proins-/- NOD mice with or without αGC-treatment. In situ 
hybridization showed no infection of islets at any time point, as seen in Fig. 3A-F 
([112] and P. Larsson, V. Stone et al., unpublished results). This suggested that 
activated iNKT cells regulate diabetes development after CVB4 infection. 
 
Next we analyzed the mRNA expression of inflammatory cytokines and suppressive 
enzymes in the islets from untreated, αGC-treated, CVB4 infected and combined αGC-
treated and CVB4 infected Proins-/- NOD mice. We observed significantly reduced 
expression levels of the inflammatory cytokines IL-4, IL-13 and IFN-γ and increased 
expression levels of the suppressive enzymes iNOS, IDO1, IDO2, Arginase I and 
Ym1/Ym2, when comparing islets from the combination treated mice to those from 
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CVB4 infected mice (Fig. 2 in Paper I). These findings suggest that iNKT activated in 
the presence of CVB4 can establish a less inflammatory and more immunosuppressive 
milieu in the islets than what is observed after CVB4 infection alone.  
 
  
Fig. 3. Pancreatic sections from Proins-/- NOD stained for insulin and EV RNA. Insulin 
staining using IHC (A, C, E) and ISH staining for viral RNA (B, D, F) in pancreatic section 
from an uninfected mouse using 10x magnification (A, B), and from a CVB4 infected mouse 
using 10x (C, D) and 25x (E, F). Each staining is a representative staining for each condition. 
Arrows indicate cells stained positive for viral RNA ([112] and P. Larsson, V. Stone et al., 
unpublished results). 
 
 
The upregulation of Ym1/Ym2 is interesting, since this enzyme is mainly expressed by 
the suppressive M2 macrophages [153]. We therefore isolated single cells from islets 
from untreated, αGC-treated, CVB4 infected and combined αGC-treated and CVB4 
infected Proins-/- NOD mice and FACS sorted them using antibodies against CD45, 
CD11b, CD11c and 120G8. The cells were sorted as CD45-, CD11c+, CD11clow/ 
120G8+, CD11b-/CD11c- and CD11b+/CD11c- and thereafter analyzed for mRNA 
expression of suppressive enzymes. The CD11b+/CD11c- myeloid cells had the highest 
expression of all analyzed suppressive enzymes (Fig. 3A and B in Paper I), and these 
cells were further characterized using F4/80, Ly-6G, Ly-6C and CD115 antibodies. 
Subsequent analysis showed that these cells represented CD45+/CD11b+/ F4/80+/Ly-
6C+/CD115+ macrophages [154]. As previously shown, these macrophages expressed 
inflammatory cytokines if exposed to CVB4 alone [155-157], however, this expression 
was change to an expression of suppressive enzymes if exposed to a combination of 
αGC and CVB4 (Fig. 2 and Fig. 4B in Paper I). This suggested that macrophages 
infiltrating the islets after CVB4 infection expressed inflammatory cytokines, but upon 
CVB4 infection with αGC, iNKT cells could make these macrophages expressing 
suppressive enzymes instead. 
 
We then further characterized the response to CVB4 in iNKT cells isolatd from the 
islets of Vα14/Proins-/- NOD mice. Vα14 transgenic mice were used since these mice 
express a 10-fold increase in frequency and numbers of iNKT cells. Isolated islets cells 
A" C"
B" D"
E"
F"
IHC"
(insulin)"
ISH"
(virus"RNA)"
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from untreated, αGC-treated, CVB4 infected and combined αGC-treated and CVB4 
infected Vα14/Proins-/- NOD mice, were stimulated with PMA/Ionomycin and 
Brefeldin A before they were stained using an APC-conjugated αGC-loaded CD1d 
tetramer and antibodies against CD69, Ki-67, IFN-γ, IL-4 and IL-13. CVB4 infection 
alone lead to induced activation of pancreatic iNKT cells that upregulated CD69 but 
not the proliferative marker Ki-67. αGC treatment alone increased proliferation and 
production of cytokines, but did not activate iNKT cells to upregulate CD69 (Fig. 5 in 
Paper I). The role of the cytokines IL-4, IFN-γ and IL-13 in suppressive macrophage 
function was then examined by PCR in islets from combined αGC-treated and CVB4 
infected Proins-/- NOD mice also treated with antibodies blocking IL-4, IFN-γ or IL-13. 
Indeed, blocking of IFN-γ resulted in significantly decreased mRNA expression levels 
of iNOS, IDO1, IDO2 and Ym1/Ym2, whereas blocking of IL-13 reduced the 
expression levels of Arginase I (Fig. 6 in Paper I). Blocking of IL-4 did not have any 
effect. This suggested that cytokines expressed by activated iNKT cells are key 
mediators for the activation of suppressive macrophages in mice after CVB4 infection. 
 
In order to investigate the role of the suppressive enzymes iNOS, IDO1, IDO2, and 
Arginase I, combined αGC-treated and CVB4 infected Proins-/- NOD mice were also 
treated with specific inhibitors for these enzymes or mock-treated. The inhibitors 
against iNOS (1400W) and Arginase I (nor-NOHA) had no effect in blocking the 
protective effect on diabetes development, but blocking IDO1/2 with inhibitor 1MT 
restored diabetes development in these mice (Fig. 7A in Paper I). The observation that 
1MT alone did not have an effect on spontaneous diabetes development in Proins-/- 
NOD mice but the effect in αGC-treated and CVB4 infected Proins-/- NOD mice was 
the same as all three inhibitors together, suggesting that IDO1/2 alone played a 
significant role in the protection from diabetes development (Fig. 7A and B in Paper I).  
 
Since the IDO1/2 expression in islets was induced by IFN-γ, we blocked IFN-γ in 
αGC-treated and CVB4 infected Proins-/- NOD mice and observed the same restoration 
of diabetes development as we did when blocking IDO1/2 with 1MT (Fig. 7D in Paper 
I). We also tested the suppressive macrophages in a T-cell proliferation assay, where 
macrophages isolated from islets from CVB4 infected and combined αGC-treated and 
CVB4 infected Proins-/- NOD mice were co-cultured with diabetogenic CD4 T-cells 
isolated from BDC2.5 mice. We observed an increased T-cell proliferation after co-
culture with macrophages from CVB4 infected mice, but a significantly reduced 
proliferation of T-cells co-cultured with macrophages from combined αGC-treated and 
CVB4 infected mice (Fig. 7E in Paper I). The reduced proliferation was abrogated by 
addition of 1MT to the culture. We further performed adoptive transfers of 
macrophages isolated from islets from CVB4 infected and combined αGC-treated and 
CVB4 infected Proins-/- NOD mice and then transferred to CVB4 infected Proins-/- 
NOD mice. Macrophages transferred from CVB4 infected mice increased the observed 
incidence of diabetes but macrophages isolated from combined αGC-treated and CVB4 
infected mice reduced the incidence of diabetes (Fig. 7F in Paper I). All this suggests 
that macrophages might have a dual role in diabetes development and protection from 
diabetes, all depending on how they are activated and stimulated after a CVB4 
infection. 
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Finally, we examined T-cells isolated from islets from untreated, αGC-treated, CVB4 
infected, combined αGC-treated and CVB4 infected and combined αGC-treated, 1MT 
treated and CVB4 infected Proins-/- NOD mice. We observed that all infected mice had 
significantly higher numbers of CD4 and CD8 T-cells in the islets than untreated and 
αGC-treated mice had (Fig. 8A and B in Paper I). When analyzing the frequency of 
IFN-γ+ cells among the CD8 T-cells, we observed that mice that had developed 
diabetes had significantly higher frequencies of IFN-γ+ cells, independent on previous 
treatments (Fig. 8C and D in Paper I). We also noted that IFN-γ+ IGRP CD8 T-cells 
were only found among CVB4 infected diabetic mice (Fig. 8C in Paper I), further 
supporting a role for CD8 T-cells in CVB4-induced diabetes, as suggested previously 
[113, 158]. This suggested that the protective effect seen on diabetes development in 
combined αGC-treated and CVB4 infected Proins-/- NOD mice does not depend on 
reduced T-cell numbers, but rather suggests that the suppressive effects by the iNKT 
cell-induced macrophages can inhibit autoreactive T-cells locally in the pancreas. 
 
In summary, our data indicates manipulations of iNKT cells can induce suppressive 
functions in macrophages. Upon αGC and CVB4 activation, islet iNKT cells produce 
IFN-γ which can activate macrophages to produce immunosuppressive enzymes, like 
IDO1/2, in the islets, which can prevent diabetes development through the local 
inhibition of autreactive T-cells. We have also showed a dual role for macrophages in 
diabetes development, where macrophages can be both causative and suppressive 
effector cells. We believe that our results can be used for novel therapeutic approaches 
in order to manipulate iNKT cells and suppressive macrophages. 
 
7.2 Paper II  
Preclinical Evaluation of Efficacy and Safety of a New Vaccine Against 
Coxsackievirus B1 – Implications for Type 1 Diabetes Development 
 
EV infections have been implicated as environmental triggers in the etiology of T1D 
[67-69]. Several epidemiological studies have also suggested a causal linkage between 
EV infections and development of islet autoimmunity [64, 80-83]. However, most 
studies have neglected to sequence or serotype their viral findings further, hence we 
cannot say which types of EVs may be causative agents for T1D development. 
Historically the CVBs, especially CVB4, have been suggested to have diabetogenic 
properties, and CVB4 has indeed been isolated from diabetic patients. However, 
recently two multi-center studies appointed CVB1 a diabetogenic role, as it was 
demonstrated that CVB1 infections were associated with development of β-cell 
autoimmunity in some children [83] and that CVB1 infections were more common in 
children who have developed T1D [93]. The identification of a specific virus associated 
with development of T1D is interesting, since it suggests that only a few specific EV 
strains might be diabetogenic. Isolation of such viruses also suggests a possibility to 
vaccinate against these serotypes in order to test the hypothesis that CVB1 can trigger 
β-cell autoimmunity and T1D development.  
 
Some attempts have been made to develop new vaccines against EVs, the most recent 
against EV71 [159, 160] and Coxsackievirus serotype A16 [161, 162]. EV71 has 
evolved as a novel epidemic in Asian countries, causing hand, foot and mouth disease 
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(HFMD) and severe encephalitis in patients [159]. There are however, to our 
knowledge, no vaccines that are targeting CVB1 infections. Hence, the aim of Paper II 
was to develop and pre-clinically evaluate function and autoimmune safety for a novel 
prototype CVB1 vaccine in mice.  
 
We first titrated the levels of neutralizing antibodies in the circulation of vaccinated 
BALB/c mice (Fig. 1A in Paper II). The vaccination was deemed safe since no adverse 
side effects was observed in the vaccinated mice, and the cumulative weight increase 
after vaccination matched that of mock-treated controls (Fig. 1B in Paper II). Upon 
viral challenge with the live homologous CVB1 strain, vaccinated mice had 
significantly reduced virus titers in targeted tissues. The viremia levels at both day 2 
and 7 post infection and the pancreatic virus titers day 7 post infection was significantly 
lower, or undetectable, in vaccinated mice compared to that observed in mock-treated 
mice (Fig. 1C in Paper II). We could also observe a weight loss in the mock-treated 
BALB/c mice after CVB1 challenge, a hallmark of a CVB infection in mice ([163] and 
P.G. Larsson and M. Flodström-Tullberg, unpublished observations). This was 
however not observed in the vaccinated mice after CVB1 challenge (Fig. 1D in Paper 
II). These results showed that the vaccine induced neutralizing antibodies that cold 
protect BALB/c mice from CVB1 infection and that the use of the vaccine was safe in 
BALB/c mice. 
 
Thereafter, we investigated the safety profile of the vaccine using NOD mice, a model 
for autoimmune diabetes. Prediabetic NOD mice have also been shown to develop 
diabetes with an accelerated onset after various CVB infections [113, 114, 164], a 
finding that was recently confirmed in human T1D patients [90]. Also, like in humans 
[42], NOD mice develop autoantibodies towards β-cell antigens which precedes 
diabetes development [165]. Since it has not been tested before, we initially tested 
whether a CVB1infection would have the same accelerating effect on diabetes 
development as other CVBs [112-114, 164]. Hence, prediabetic female NOD mice 
were infected with CVB1 at 14 weeks of age, after which diabetes development was 
compared to that of untreated or mock-treated female NOD mice (Fig. 2B and C in 
Paper II). As expected, CVB1 infected NOD mice showed an accelerated onset of 
diabetes (Fig. 2B and C in Paper II). Knowing that CVB1 could accelerate diabetes 
onset in prediabetic female NOD mice, we next evaluated diabetes development in 
vaccinated, mock-treated or untreated female NOD mice. The vaccinations were done 
using three injections, just like in the BALB/c mice, and we observed high titers of 
neutralizing antibodies after vaccination (Fig. 3B in Paper II). Also in the NOD mice, 
vaccination was deemed safe as no adverse side effects was observed and the 
cumulative weight increase matched that of mock-treated and untreated mice (Fig. 3C 
in Paper II).  
 
We could not observe any differences in incidence or acceleration of diabetes onset 
among the vaccinated NOD mice compared to mock-treated and untreated controls 
(Fig. 3D in Paper II). This suggested that, unlike infection with the live CVB1 virus, 
the vaccine does not affect the process leading to diabetes development in NOD mice. 
However, a previous study did observe a protective effect on diabetes development in 
NOD mice after immunizing them with formalin-inactivated CVB4 [166]. However, 
since we did not use any adjuvants in our study, these observations could be explained 
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by the differences in the experimental setup. The suggested dependency of Treg cells 
was however not addressed in our study [166].  
 
We further confirmed the notion that our vaccine had no affect on diabetes 
development by comparing induction of autoimmunity in the form of IAAs, in 
untreated, mock-treated, CVB1 infected and vaccinated NOD mice. We could not 
observe any significant increase in the IAA titers after neither CVB1 infection nor 
vaccination compared to respective mock-treated and untreated controls. We also 
compared the frequency of animals seroconverting to IAA positivity after treatments 
but there were no significant differences. However, it has been suggested previously 
that an immunization with formalin-inactivated CVB4 in combination with Freund’s 
adjuvant could increase the titers of IAAs in mice [166]. Although our results do not 
support this finding, we did not use any adjuvants, which may explain the observed 
discrepancies. However, we did compare the effect on IAA levels after CVB1 
vaccination to that seen after CVB1 infection, and we could not observe any 
differences, although CVB1 vaccination did accelerate diabetes development in NOD 
mice. This may suggests a negligible role for IAAs in diabetes development in NOD 
mice. 
 
In respect of the observations that narcolepsy is an autoimmune disease, which may be 
triggered by both the H1N1 virus and the H1N1 vaccine Pandemrix through previously 
unidentified gene-virus/vaccine interactions [126], there is a possibility that such gene-
virus/vaccine interactions may exist for T1D and the virus/vaccine tested here. Despite 
our safety studies in the NOD mouse model, we cannot rule out this possibility if the 
vaccine is further developed for human use.  
 
In total, our results showed that vaccinated mice produced neutralizing antibodies, 
which provided protection against CVB1 infection in vivo. We also showed that the 
vaccine did not cause any adverse side effects in BALB/C and NOD mice, suggesting 
that the vaccine was well tolerated. Further, the vaccine did not trigger or accelerate β-
cell autoimmunity, in the form of IAAs, or accelerate diabetes onset in pre-diabetic 
NOD mice. Lastly, we also showed that the live CVB1 could accelerate diabetes onset 
on prediabetic female NOD mice, but the effect on diabetes development did not 
correlate with induced β-cell autoimmunity in the form of IAA. In summary, our results 
indicate that this vaccine could be developed further and adapted for human use, in 
order to develop a vaccine that could be used to test the hypothesis that CVBs are 
involved in the development and etiology of human T1D. 
 
7.3 Paper III  
Previous Maternal Infection Protects Offspring from Enterovirus Infection and 
Prevents Experimental Diabetes Development in Mice 
 
Despite numerous studies suggesting an association between EV infections and T1D 
development, some controversies exist. Based on the link between EV infections and 
T1D development, the natural expectation would be that the T1D incidence should be 
highest in countries with a high prevalence of observed EV infection. However, the 
opposite has been observed when comparing data from several different countries, 
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suggesting an inverse correlation between the incidence of T1D and the prevalence of 
observed EV infections. This counter-intuitive observation has been observed and 
explained before for poliovirus infections and development of severe paralytic 
poliomyelitis [96]. In 2000, Viskari et al. further suggested to apply the so called 
polivirus hypothesis [96] on enterovirus infections and T1D development, in order to 
explain the observed inverse correlation between the two [97]. Some indirect evidence 
have been presented in support of the extended poliovirus hypothesis suggested by 
Viskari et al., but there has been no direct experimental proof-of-concept for maternally 
transferred antibodies protecting offspring from potentially diabetogenic CVB 
infections [103, 132, 167]. Hence, we wanted to determine if maternally transferred 
antibodies could protect genetically susceptible offspring from virus-induced diabetes. 
In Paper III we therefore tested the extended poliovirus hypothesis applied on CVB 
infections and diabetes development in two different mouse models. 
 
Firstly, we infected NOD mice with a low dose CVB3, in order to establish whether 
NOD mice develop neutralizing antibodies to CVB3. Virus infection was confirmed in 
all infected mice by blood samples in which viremia was assessed day 3 post infection 
(Supplementary figure 1A in Paper III). Infected mice then developed high titers of 
neutralizing antibodies at day 14 post infection (Supplementary figure 1B in Paper III). 
We also tested the specificity of the antibodies from the infected mice in a cross-
neutralization test with CVB4, which showed that the induced antibodies were 
serospecific for CVB3 (data not shown).  
 
Having established that NOD mice raise neutralizing antibodies to CVB3, we infected 
female NOD mice with a low dose of CVB3. After confirming antibody-positivity, 
immunized females were set up in heterozygous breeding with Socs-1 tg males, a 
mouse model for virus-induced diabetes, rendering 50% of the offspring Socs-1 tg. In 
parallel, naïve NOD females were also bred with Socs-1 tg males, see the experimental 
model presented in Fig. 4. All offspring were thereafter tested for the presence of 
neutralizing antibodies in serum at the day of weaning. We showed that offspring from 
immunized dams had high titers of neutralizing antibodies present in their circulation, 
whereas offspring from naïve mothers did not (Fig. 1A in Paper III). We also showed 
that these antibodies could protect offspring from infection with a high dose of CVB3, 
since the virus titers were significantly lower in both blood and pancreas in infected 
offspring from immunized mothers compared to offspring from naïve females (Fig. 1B 
and C in Paper III).  
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Figure 4. Experimental setup for maternal transfer of antibodies to offspring. Female 
NOD mice immunized with a low dose CVB3 or mock-treated were, after viral clearance, bred 
with Socs-1 tg NOD mice. Maternal antibody transfer was assayed in all offspring but 
protection from CVB3 infection and diabetes development after infection was only tested in 
Socs-1 tg offspring (adopted from Paper III [101], with permission from the publisher). 
 
When analyzing the Socs-1 tg offspring from immunized and naïve females alone, we 
also observed that offspring from immunized females were protected from diabetes 
development after a diabetogenic CVB3 infection (Fig. 2A-C in Paper III). A clear 
difference was observed in diabetes development after challenging the Socs-1 tg 
offspring with a diabetogenic dose of CVB3 (Fig. 2B in Paper III), where none of the 
Socs-1 tg offspring from immunized females developed diabetes. Such a protection 
from infection and diabetes development in offspring from immunized females has 
indirectly been observed before by, when Tirabassi et al. showed that rats born from 
Kilham rat virus (KRV) immunized females were protected from infection and KRV-
induced diabetes [167]. However, compared to our study, Tirabassi et al. neglected to 
show any data regarding the transfer of maternal antibodies or titers of neutralizing 
antibodies [167]. 
 
We further showed the maternal protection from infection by IHC stainings of 
pancreata from CVB3-infected Socs-1 tg offspring originating from immunized and 
naive mothers (Fig. 2C in Paper III), where we could clearly see that offspring from 
immunized females were protected from infection.  
 
Despite the fact that we awaited viral clearance from the immunized females, even 
before we set them up in breeding, we cannot rule out the possibility that the maternal 
infection could have affected the permissiveness of the offspring by other means than 
the transferred antibodies. Therefore we conducted experimental adoptive serum 
transfers of confirmed antibody-positive and negative serum from immunized and 
naïve mice to naïve Socs-1-tg mice. All sera had been heat-inactivated prior to the 
transfers, in order to rule out any potential transfer of virus (data not shown). Antibody 
titers in the circulation of mice receiving serum transfers was analyzed 24h post 
transfer, and we observed high titers of neutralizing in mice receiving antibody-positive 
sera compared to no neutralizing activity in serum of mice receiving antibody-negative 
sera mothers (Fig. 3A in Paper III). Furthermore, recipients of antibody-positive sera 
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had almost non-detectable levels of viremia three days after challenge with a 
diabetogenic dose of CVB3, compared to mice receiving antibody-negative sera (Fig. 
3B in Paper III). Finally, we also showed that Socs-1 tg mice receiving antibody-
positive sera were completely protected from developing diabetes after CVB3 
infection, whereas 50% of the Socs-1 tg mice receiving antibody-negative sera 
developed diabetes rapidly after infection. 
 
A potential limitation with this study is the use of the Socs-1 tg mouse model for virus-
induced diabetes, since diabetes development in this model is solely dependent on a 
virus infection in the β-cells. Using for example the NOD or the LCMV/RIP-GP/NP 
mouse models, future studies could test whether maternal antibodies can protect 
offspring from virus-induced T-cell mediated diabetes development. Also, our results 
do not supply any additional information to whether EVs can trigger diabetes or not. 
Such data may only come from vaccination studies showing an effect on human T1D 
development. 
 
Taken together, we have here shown data that suggests proof-of-concept for the 
poliovirus hypothesis applied on CVB infections and development of diabetes in 
genetically susceptible mice. This implies that the extended poliovirus hypothesis 
suggested by Viskari et al., may be used to explain the observed inverse correlation 
between T1D incidence and the number of EV infections in different populations. 
Furthermore, our results suggest that maternal antibodies indeed can protect offspring 
from potentially diabetogenic virus infections, which if extrapolated, may suggest novel 
vaccination strategies for pregnant women. This idea is supported by the recent 
recommendations by the CDC in the United States, to give all pregnant women a 
booster vaccination against tetanus, diphtheria and pertussis (a vaccine combination 
known as Tdap) during gestation week 27-36, in order to maximize the transferred 
protection to the children [130].  
 
7.4 Paper IV 
Human Intestinal Epithelial Cells Enter an Antiviral State upon Stimulation with 
Interferon Lambda 
 
Type I IFNs (mainly IFN-α and β) are important for antiviral responses in most cells 
[29, 30]. The effect of the IFN-λs (type III IFN) may however only have local effects, 
due to the relatively restricted expression of the IFN-λ receptor. It has been suggested 
that mainly epithelial cells express the IFN-λ receptor [30, 168-170], but this has been 
expanded by other studies showing that for example primary hepatocytes [171] and 
human pancreatic islets [172] also expressed the IFN-λ receptor. Our study showing 
that human islets produced IFN-λ after CVB3 infection and that IFN-λ could reduce 
islet permissiveness to CVB infection, also suggests an important role for IFN-λs in in 
the antiviral response to CVBs [172]. Other studies have shown a potent role for IFN-
λs in the antiviral defense against rotavirus infections in the intestine [170]. This is 
interesting, since the primary site of replication for CVBs is in the IECs.  
 
In Paper IV we were interested in examining how human IECs respond to IFN-λ 
stimulation, in respect of induction of antiviral defense genes previously suggested to 
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be involved in the establishment of an antiviral state. Previous studies have shown that 
the expression of the antiviral genes PKR, MxA, ISG15, OAS-2 and iNOS are of 
importance in the antiviral response to CVB infections [144, 173, 174]. Hence, in 
Paper IV we tested if two human IEC lines CaCo-2 and HT-29 could upregulate these 
antiviral defense genes after IFN-λ stimulation.how the two human IEC lines after IFN-
λ stimulation. We also determined the expression of the two main receptors used by 
CVBs for cellular entry, CAR and DAF, in CaCo-2 and HT-29 cells, in order to 
determine if these IECs could be used to test if IFN-λs can regulate IEC permissiveness 
to CVB infections. 
 
We first confirmed the previous finding that CaCo-2 and HT-29 cells expressed mRNA 
for the IFN-λ receptor subunits IFNλR1 and IL-10R2 [169]. Both CaCo-2 and HT-29 
cells had detectable mRNA expression levels of the receptor subunits, comparable to 
what has been observed before for human islets [172], which was used as positive 
controls (Fig. 1 in Paper IV). Successful confirmation of mRNA expression of both 
receptor subunits in both cell lines was indicative that these cells would be able to 
respond to IFN-λ stimulation in vitro. Of note here is that mRNA expression for the 
receptor subunits does not automatically suggest functional protein translation. 
However, since we did observe a response after IFN-λ stimulation of both IEC lines, 
we concluded that the receptor mRNA expression indeed indicated expression of a 
functional IFN-λ receptor complex on CaCo-2 and HT-29 cells (Fig. 1 and 2 in Paper 
IV).  
 
Having established this, we continued to study the activation of antiviral defense genes 
in CaCo-2 and HT-29 cells after IFN-λ stimulation. In part, previous studies have 
shown that these cells could upregulate transcription factors and ISGs after IFN-λ 
stimulation [169]. Our results confirmed the previous findings of MxA and OAS-2 
upregulation after IFN-λ stimulation [169] (Fig. 2 in Paper IV). Our study further 
expanded this with the findings that CaCo-2 and HT-29 cells also upregulated the 
expression of PKR and ISG15 after IFN-λ stimulation. However, we could not observe 
induction of iNOS after IFN-λ stimulation of either cell line. IFN-α was used as a 
positive control for induction of the respective mRNA. 
 
As previously mentioned, mRNA expression levels are not enough to claim that a 
protein is upregulated. Hence, using Western blotting, we determined expression of 
MxA protein levels in both CaCo-2 and HT-29 cells, before and after IFN-λ stimulation 
(Fig. 3 in Paper IV). MxA was upregulated in both cell lines compared to control cells 
by both IFN-λ1 and IFN-λ2.  However only done for one of the studied genes, this 
indicates that the induced mRNA expression of genes involved in an antiviral state is 
also translated into proteins. IFN-α stimulation was used as a positive control.  
 
During this study, we observed a marked difference when comparing the induced 
mRNA expression levels and MxA protein expression after IFN-α and stimulation to 
that after IFN-λ1 and IFN-λ2 stimulation (Fig. 2 and 3 in Paper IV). With the cytokine 
concentrations and time points we used, the effect on both gene expression and protein 
translation was consistently more prominent after IFN-α stimulation than after IFN-λ1 
and IFN-λ2 stimulation. Such differences have been observed previously [171, 175], 
and it is also in line with observations from our recent study on IFN-λ and IFN-α 
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stimulated pancreatic islets [172]. However, conflicting data has also been published, 
showing a more prominent antiviral effect induced by IFN-λ stimulation [176]. These 
differences could depend on varying receptor expression on the different cells and 
tissues studied. Another explanation is that the differences reflect a dose-dependent 
effect, suggesting a non-comparable effect after stimulating cells with either 1000U/ml 
IFN-α or 100ng/ml of the respective IFN-λs. Indeed, in Paper IV, we did not perform a 
dose-response curve with higher doses than 100ng/ml of each IFN-λs, as seen in Fig. 5 
(P. Larsson, V. Stone et al., unpublished data), hence it is possible that the observed 
effect would have been more prominent if using higher doses of IFN-λs. However, 
throughout the studies in Paper IV we used 1000U/ml of IFN-α and 100ng/ml IFN-λs, 
since these concentrations have been used before with a clearly induced effect and 
minimized cytotoxicity [169, 171, 172, 177, 178]. 
 
                      
 
Figure 5. Proliferation in IFN-stimulated HT-29 cells. HT-29 cells were untreated or treated 
with IFN-buffer, 1000U/ml IFN-α, or 1, 10 or 100ng/ml IFN-λ1 or IFN-λ2 for 24h. Cell 
proliferation was normalized to that of buffer-treated cells. Data was presented as means ± SD, 
n=4 for each sample (P. Larsson, V. Stone et al., unpublished data). 
 
 
Finally, we also tested whether CaCo-2 cells and HT-29 cells express the two main 
receptors used by CVBs for cellular entry, CAR and DAF, using flow cytometry with 
HeLa cells as positive controls [71, 72]. Both cell lines expressed CAR and DAF, but 
CAR was not expressed to the same extent as on HeLa cells (Fig. 2 in Paper IV). HeLa 
cell expression of CAR and DAF was high and stable, 97% ± 3% (n=3) and 98% ± 2% 
(n=3), respectively. Of the HT-29 cells, 67% ± 2% (n=3) expressed CAR and 99% ± 
1% (n=3) expressed DAF. Expression of CAR on CaCo-2 cells was less stable and 
57% ± 17% (n=3) were positive for CAR, whereas 98% ± 2% (n=3) expressed DAF. 
All data was presented as means ± SD. The fact that both tested cell lines were positive 
for CAR and DAF, suggests that these cells could indeed get infected with CVBs.  
 
However, a potential limitation with our results describing CAR and DAF expression 
on the cellular surface is that this was only shown by flow cytometry. We cannot say 
how or where the cells may express CAR and DAF, if stained in confluent cell layers. 
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It has been suggested previously that CAR is not accessible from the apical side of 
polarized epithelial cells [76]. This may suggest that CVBs that depend solely on CAR 
may not be able to infect these cells in vitro in polarized cells. 
 
In summary, the fact that CaCo-2 and HT-29 cells respond to IFN-λ signaling by 
entering an antiviral state and the finding that both cell lines express the receptors used 
by CVBs, suggests that these cell lines could be used in future experiments to evaluate 
whether IFN-λ can regulate permissiveness to CVBs in IECs. Furthermore, our findings 
are also interesting in respect to the suggestion that EVs might cause a persistent 
infection in the intestinal mucosa of T1D patients [88, 89], since our model suggests a 
novel way of studying these infections to determine what can regulate IEC 
permissiveness to CVBs. 
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8 CONCLUDING REMARKS 
 
Paper I: 
• iNKT cells can be activated and manipulated in order to induce suppressive 
macrophages, which in turn can inhibit diabetes development locally in the 
pancreas of CVB4-infected diabetes-prone mice.  
 
• Islet-resident macrophages may have a dual role in diabetes development in 
CVB4-infected diabetes-prone mice, since they can be of an inflammatory 
phenotype (expressing IL-1β, IL-6 and TNF-α) or suppressive phenotype 
(expressing IDO1/2).  
 
Paper II: 
• The novel prototype CVB1 vaccine induced high titers of neutralizing 
antibodies in two different mouse strains, even without the use of adjuvants. 
The vaccine protected mice against CVB1 infection and was safe for use in two 
different mouse strains, with no adverse side effects observed. 
 
• CVB1-vaccination of diabetes-prone NOD mice did not affect diabetes 
development, whereas live infection with CVB1 did. Vaccination did neither 
trigger autoimmunity in the form of IAAs in NOD mice. 
 
• If further developed for human use, this vaccine could be used to test the 
hypothesis that CVB1 can trigger autoimmunity and T1D development in 
genetically susceptible individuals. 
 
Paper III: 
• Our results showed experimental proof-of-concept for how maternal antibodies 
can protect genetically susceptible offspring from virus infection and diabetes 
development in a mouse model for virus-induced diabetes. This may further 
lend support for using the extended poliovirus hypothesis in order to explain the 
inverse correlation between T1D incidence and the prevalence of observed EV 
infections.  
 
• Our results further shows that maternal antibodies indeed can protect offspring 
from diabetogenic virus infections, which if extrapolated, may suggest 
beneficial effects of adding an EV vaccine in future vaccination programs for 
pregnant women. 
 
Paper IV: 
• We have here shown that the two human IEC lines CaCo-2 and HT-29 can 
enter an antiviral state upon IFN-α and IFN-λ treatments.  
 
• CaCo-2 and HT-29 cells express the two main receptors CVBs use to infect 
cells, CAR and DAF, which suggests that these cell lines can be used to study if 
IFN-λ can regulate permissiveness to CVB infections in IECs.  
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9 FUTURE PERSPECTIVES ON DIABETES 
RESEARCH 
T1D is a truly complex disease with both genetic factors and environmental factors 
involved in regulating susceptibility to disease development. Genetic differences may 
be studied and found quite easily, by comparing genes and gene expression in T1D 
cases versus controls. However, studying the environmental factors involved in 
regulating disease susceptibility is more complicated, since once diabetes is presented 
in patients, it is very hard to track backwards which environmental factors might have 
been involved in triggering the disease. Combining both genetic an environmental 
factors makes it even harder to understand the etiology of T1D; which factors are 
actually regulating each other, what is the hen and what is the egg?  
 
To come around this problem, several national and international long-term prospective 
cohort studies have been initiated, for example the DIPP, TEDDY, ENDIA and TRIGR 
studies [179-182]. These studies have enrolled children from birth depending on 
different inclusion and exclusion criteria, but the common denominator is that all 
studies are continuously saving blood, serum and stool samples over time. Some 
studies also provide questionnaires for the participants in order to save matched 
information regarding for example infection history and symptoms from the 
participants. By saving all this, scientists can then lock backwards in a diabetic patient’s 
history of samples, in order to find specific events that may have triggered onset of 
autoimmunity or T1D. This is a great tool for diabetes researchers and these cohort 
studies are indeed extraordinary initiatives. Upon final analysis, these studies will be 
able to provide invaluable sets of data, which hopefully can lead to new discoveries on 
which environmental factors are involved in T1D development.  
 
I think that the most important thing here is to read the final results from these studies 
with an open mind. If possible, we should all take one step back from what we are 
currently working on, away from our old habits and potentially narrow-minded views, 
and instead try to use these studies to see the whole picture of T1D. It might be that we 
will find that T1D is a very heterogeneous disease, with several different complex 
mechanisms that all can regulate diabetes development independently of each other. In 
any case, providing that we can understand the etiology of T1D and the different 
pathways involved in regulating development of disease, we may be able to tailor 
specific preventative therapies for those at risk, based on different genetic and 
environmental factors for different patients.  
 
I believe that the recent findings of CVB1 to be specifically diabetogenic are important 
observations, and this may be one factor that can regulate T1D development in certain 
genetically susceptible individuals. However, since most people who are infected with 
CVB1 do not develop T1D, we need to further address what other factors that, in 
combination with CVB1, may regulate susceptibility to T1D. Hopefully, this can be 
answered by the aforementioned prospective studies.  
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When reflecting on these paragraphs and ideas, I find it truly strange that many 
scientists in the diabetes field are so blinded by their own hypotheses that they 
stubbornly refuse to listen and learn from new findings in other research fields than 
their own. Examples of this scenario can unfortunately be observed on any diabetes 
conference you go to. However, if not listening to new findings with an open mind, 
how can we obtain new knowledge to implement in our own studies to understand T1D 
etiology?  
 
Another thing that is hampering the scientific community is actually the funding system 
for science, since people won’t share their unique ideas before these are fully 
published, due to the fact that we are all competing for the same research grants. I do 
not have any constructive suggestions on how to solve this, since of course grants 
should go to the scientist who presents the best application with the most promising 
ideas, but I would like to emphasize that the funding system for science may not be 
ideal. 
 
Finally, for me having T1D, it is a bit depressing to realize that whatever we do, we 
will not likely be able to “cure” diabetes. We will hopefully be able to prevent it in the 
future, but unless we can finally map the etiology of T1D, there is actually very little 
point in trying to develop transplantation strategies or even growing new β-cells from 
stem cells. Unless we understand why the β-cells were killed in the first place, they will 
likely be killed again if we just replace them.  
 
Hence, the near future for T1D patients and T1D treatment most likely lies in technical 
developments and new smart insulin pumps with integrated continuous glucose 
sensors, which upon individual programming, resembles an artificial pancreas.  
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